CN110128315B - Compound, preparation method and application thereof, glycosidase inhibitor - Google Patents
Compound, preparation method and application thereof, glycosidase inhibitor Download PDFInfo
- Publication number
- CN110128315B CN110128315B CN201910261497.5A CN201910261497A CN110128315B CN 110128315 B CN110128315 B CN 110128315B CN 201910261497 A CN201910261497 A CN 201910261497A CN 110128315 B CN110128315 B CN 110128315B
- Authority
- CN
- China
- Prior art keywords
- preparation
- compound
- acid
- imino
- mannitol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 229940122069 Glycosidase inhibitor Drugs 0.000 title claims abstract description 8
- 239000003316 glycosidase inhibitor Substances 0.000 title claims abstract description 8
- -1 nitro, amino Chemical group 0.000 claims abstract description 32
- 102000005744 Glycoside Hydrolases Human genes 0.000 claims abstract description 20
- 108010031186 Glycoside Hydrolases Proteins 0.000 claims abstract description 20
- 239000001257 hydrogen Substances 0.000 claims abstract description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 239000002904 solvent Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 16
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- 102000019199 alpha-Mannosidase Human genes 0.000 claims description 11
- 108010012864 alpha-Mannosidase Proteins 0.000 claims description 11
- 102000005936 beta-Galactosidase Human genes 0.000 claims description 11
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 238000010511 deprotection reaction Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 8
- 238000006268 reductive amination reaction Methods 0.000 claims description 8
- 102100032487 Beta-mannosidase Human genes 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 claims description 7
- 108010060309 Glucuronidase Proteins 0.000 claims description 7
- 102000053187 Glucuronidase Human genes 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 7
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 7
- 108010061314 alpha-L-Fucosidase Proteins 0.000 claims description 7
- 102000012086 alpha-L-Fucosidase Human genes 0.000 claims description 7
- 108010044879 alpha-L-rhamnosidase Proteins 0.000 claims description 7
- 102000006995 beta-Glucosidase Human genes 0.000 claims description 7
- 108010047754 beta-Glucosidase Proteins 0.000 claims description 7
- 108010055059 beta-Mannosidase Proteins 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 239000003638 chemical reducing agent Substances 0.000 claims description 7
- 239000000460 chlorine Substances 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 6
- 239000002841 Lewis acid Substances 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 6
- 239000003054 catalyst Substances 0.000 claims description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- 150000007522 mineralic acids Chemical class 0.000 claims description 6
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 5
- 208000015872 Gaucher disease Diseases 0.000 claims description 5
- 239000012298 atmosphere Substances 0.000 claims description 5
- 239000011630 iodine Chemical group 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 239000011261 inert gas Substances 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 150000007530 organic bases Chemical class 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012279 sodium borohydride Substances 0.000 claims description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 3
- JHXKRIRFYBPWGE-UHFFFAOYSA-K bismuth chloride Chemical compound Cl[Bi](Cl)Cl JHXKRIRFYBPWGE-UHFFFAOYSA-K 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 3
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 claims description 3
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 claims description 3
- 229940102001 zinc bromide Drugs 0.000 claims description 3
- 239000012448 Lithium borohydride Substances 0.000 claims description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 229940043279 diisopropylamine Drugs 0.000 claims description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 claims description 2
- 229910052759 nickel Inorganic materials 0.000 claims description 2
- 229910052763 palladium Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 2
- 239000012312 sodium hydride Substances 0.000 claims description 2
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 3
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 claims 1
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 claims 1
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 claims 1
- 108010054377 Mannosidases Proteins 0.000 claims 1
- 102000001696 Mannosidases Human genes 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 claims 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract description 18
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 11
- 125000003118 aryl group Chemical group 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 8
- 125000003545 alkoxy group Chemical group 0.000 abstract description 7
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract description 7
- 229920002554 vinyl polymer Polymers 0.000 abstract description 7
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract description 5
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract description 5
- 125000005843 halogen group Chemical group 0.000 abstract description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract description 3
- 125000004185 ester group Chemical group 0.000 abstract description 3
- 239000002532 enzyme inhibitor Substances 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 11
- 230000002401 inhibitory effect Effects 0.000 description 11
- 235000000346 sugar Nutrition 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229960005566 swainsonine Drugs 0.000 description 8
- FXUAIOOAOAVCGD-UHFFFAOYSA-N swainsonine Natural products C1CCC(O)C2C(O)C(O)CN21 FXUAIOOAOAVCGD-UHFFFAOYSA-N 0.000 description 8
- FXUAIOOAOAVCGD-FKSUSPILSA-N swainsonine Chemical compound C1CC[C@H](O)[C@H]2[C@H](O)[C@H](O)CN21 FXUAIOOAOAVCGD-FKSUSPILSA-N 0.000 description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 8
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 239000005457 ice water Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 4
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 239000011737 fluorine Substances 0.000 description 4
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 125000001424 substituent group Chemical group 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- IBAQFPQHRJAVAV-ULAWRXDQSA-N Miglitol Chemical compound OCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO IBAQFPQHRJAVAV-ULAWRXDQSA-N 0.000 description 3
- 108010087472 Trehalase Proteins 0.000 description 3
- 102100029677 Trehalase Human genes 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229960001110 miglitol Drugs 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002547 new drug Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 150000003235 pyrrolidines Chemical class 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 2
- AFNHHLILYQEHKK-BDAKNGLRSA-N 7-[[(3r,4r)-3-hydroxy-4-(hydroxymethyl)pyrrolidin-1-yl]methyl]-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-one Chemical compound C1[C@H](O)[C@@H](CO)CN1CC1=CNC2=C1NC=NC2=O AFNHHLILYQEHKK-BDAKNGLRSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 208000024720 Fabry Disease Diseases 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- HTJGLYIJVSDQAE-VWNXEWBOSA-N [(1s,6s,7s,8r,8ar)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate Chemical compound O[C@H]1[C@H](O)[C@@H](OC(=O)CCC)CN2CC[C@H](O)[C@@H]21 HTJGLYIJVSDQAE-VWNXEWBOSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- QPYJXFZUIJOGNX-HSUXUTPPSA-N afegostat Chemical compound OC[C@H]1CNC[C@@H](O)[C@@H]1O QPYJXFZUIJOGNX-HSUXUTPPSA-N 0.000 description 2
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- HAJKHJOABGFIGP-UHFFFAOYSA-N indolizidine Chemical class C1CCCN2CCCC21 HAJKHJOABGFIGP-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- LXBIFEVIBLOUGU-DPYQTVNSSA-N migalastat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@H]1O LXBIFEVIBLOUGU-DPYQTVNSSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- RYVMUASDIZQXAA-UHFFFAOYSA-N pyranoside Natural products O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O RYVMUASDIZQXAA-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- ZJIHMALTJRDNQI-VFQQELCFSA-N (2r,3r,4r,5s)-2-(hydroxymethyl)piperidine-3,4,5-triol;hydrochloride Chemical compound Cl.OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O ZJIHMALTJRDNQI-VFQQELCFSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000015439 Lysosomal storage disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229910019020 PtO2 Inorganic materials 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 241000217909 Swainsona Species 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000012300 argon atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 229950003414 celgosivir Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- GFHNAMRJFCEERV-UHFFFAOYSA-L cobalt chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Co+2] GFHNAMRJFCEERV-UHFFFAOYSA-L 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 229940006052 e.e.s. Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229950007469 migalastat Drugs 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 235000011118 potassium hydroxide Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- IXZDIALLLMRYOU-UHFFFAOYSA-N tert-butyl hypochlorite Chemical compound CC(C)(C)OCl IXZDIALLLMRYOU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229950002816 ulodesine Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to the field of enzyme inhibitors, and discloses a compound, a preparation method and application thereof, and a glycosidase inhibitor. The compound has a structure shown in a formula (I),
Description
Technical Field
The invention relates to the field of glycometabolism, in particular to an N-alkylated polyhydroxy pyrrolidine compound, a preparation method and application thereof, and a glycosidase inhibitor.
Background
Iminosugars (iminosugars) are a class of sugar mimetics (sugar mimics) in which the oxygen atom of the sugar ring is replaced by a nitrogen atom, also known as iminosugars, azasugars, polyhydroxy alkaloids, etc. The research finds that the iminosugar has very strong inhibitory action on the glycosidase activity, thereby greatly exciting the research enthusiasm of people on the iminosugar [ Nash R.J., Kato A., Yu C. -Y., et al, future Med Chem,2011, 31513-. Glycosidases play important roles in organisms, involving important vital activities including intestinal digestion, lysosomal metabolism of glycoconjugates, synthesis and breakdown of glycoproteins [ (a) sugar a.c., Alonzi d.s., Killingbeck s.s., et al, plos segmented tropic diseases,2016,10, e0004524-e 0004524; (b) Sanchez-Fernandez E.M., Garcia Fernandez J.M., Ortiz Mellet C., ChemCommun,2016,52, 5497-; (c) borges De Melo E., Da Silveara Gomes A., Carvalho I, Tetrahedron,2006,62, 10277-. It is therefore believed that new drugs can be found from iminosugars for the treatment of diseases associated with glycosidase activity such as malignancies, bacterial infections, diabetes, bacterial and viral infections and lysosomal storage diseases etc. (a) Plummer e, Buck m.d., Sanchez m.et al, J Virol 2015,89, 5592-; (b) hurtley S., Service R., Szuromi P., Science,2001,291, 2337-; (c) nishimura Y., Satoh T., Kudo T., et al, Biorg Med Chem,1996, 91-96; (d) durantel D., Branza-Nichia N., Carrouee-Durantel S., et al, J Virol,2001,75, 8987-.
Iminosugars have highlighted a great role in the creation of new drugs, and up to now 4 iminosugar drugs have been marketed, for example, the fortosine (1) which was newly marketed in 17 years for the treatment of T-cell lymphoma and the Migalastat (2, DGJ. HCl) which was marketed in 16 years for the treatment of fabry disease are oral drugs for the treatment of fabry disease, and the miglutt (3, Miglustat, trade name zadesca) which was marketed in the previous years for the treatment of gaucher disease, Miglitol (4, Miglitol, trade name Diastabol) for the treatment of type ii diabetes [ y.x.li, y.m.jia, c.y.yu, Progress in Chemistry,2018,30,586 cup 600 ].
There are also a number of iminosugar drugs in clinical research. For example, 1-deoxynojirimycin hydrochloride (5, Duvoglusta @ Hydrochloride) for the treatment of Pompe disease, Isofagomine (6) for the treatment of gaucher's disease, MBI-3253(7, Celgosivir) for the treatment of hepatitis C, and Ulodesine (8) for the treatment of chronic gout, and the like.
Imino sugars play an important role in the development of new drugs, but due to the characteristics of high polarity and high water solubility, imino sugars are not easy to separate and purify. With the advance of separation technology, only two hundred imino sugars have been separated so far. The following five groups can be classified according to their nitrogen atom-containing skeletons: polyhydroxypiperidines (polyhydroxylated piperidines), polyhydroxypyrrolidines (polyhydroxylated pyrrolidines), polyhydroxyindolizidines (polyhydroxylated indolizidines), polyhydroxypyrrolizidines (polyhydroxylated pyrrolidines), and polyhydroxytropanes (polyhydroxylated tropanes).
Compared with imino sugars of other structures, the number of indolizidine imino sugars is smaller. The first iminosugar of the indolizidine class to be isolated was swainsonine (9), originally isolated by Broquist et al in 1973 from the fungal pathogen Rhizoctonialeucicola [ F.P.Guengerich, S.J.DiMari and H.P.Broquist, J.am.chem.Soc., 1973,95, 2055-. Subsequently, they were isolated from Swainsonia hance, distributed in Australian pastures [ S.M.Colegate, P.R.Dorling and C.R.Huxtable, Aust.J. chem.,1979,32, 2257-. The swainsonine is found to have better alpha-mannosidase inhibition effect through biological activity research [ (a) M.J.Schneider, F.S.Ungemach, H.P.Broquist and T.M.Harris, Tetrahedron,1983,39,29-32.(b) Y. -F.Liao, A.Lal and K.W.Moremen, J.biol.Chem.,1996, 271,28348-28358.(c) A.D.Elbein, R.Solf, P.R.Dorling and K.Vosbeck, Proc.Natl.Acad.Sci.U.S.A., 1981,78, 7393-7397); (d) G.P.Kaushal, T.Szumilo, I.Passtuszak and A.D.Elbein, Biochemistry,1990,29, 2168-; (e) i.pastuzak, g.p.kaushal, k.a.wall, y.t.pan, a.sturm and a.d.elbein, Glycobiology,1990,1,71-82 ], and into the clinical secondary study of renal cell carcinoma. However, clinical studies have shown that swainsonine has serious toxic side effects, for example, adverse reactions such as fatigue, mental debilitation, anorexia nervosa, amylase elevation and diarrhea occur in patients during administration [ P.E.Shaheen, W.Stadler, P.Elson, J.Knox, E.Winquist and R.M.Bukowski, Investigational New Drugs,2005,23, 577-. Therefore, the swainsonine needs to be structurally modified to improve the biological activity and reduce the toxic and side effects.
The 1,4-Dideoxy-l,4-imino- α -mannitol (10, DIM) molecule was designed and synthesized in 1984 by the teaching of Fleet, uk [ g.w.j.fleet, p.w.smith, s.v.evans and l.e.fellows, j.chem.soc.chem. Commun, 1984,1240-1241 ]. DIM molecules exhibit an alpha-mannosidase inhibitory activity comparable to swainsonine and can therefore be considered pharmacophores of swainsonine. The DIM molecule is a polyhydroxy pyrrolidine imino sugar, and compared with swainsonine, the single-ring framework of the DIM molecule is simpler, and the DIM molecule is convenient for mass synthesis and structural modification. However, DIM molecules are poor in lipid solubility, are not beneficial to oral absorption, only have good inhibitory activity on alpha-mannosidase, and have poor inhibitory effect on other types of glycosidases.
Disclosure of Invention
The invention aims to overcome the problems that the glycosidase inhibitor in the prior art has single inhibition effect on glycosidase, the fat solubility of inhibitor molecules is poor, and oral absorption is not facilitated, and provides an N-alkylated polypolyhydroxypyrrolidine compound, a preparation method and an application thereof.
In order to achieve the above object, a first aspect of the present invention provides a compound having a structure represented by formula (I):
wherein, R is any one of hydrogen, aryl, hydroxyl, halogen atom, vinyl, ethynyl, alkoxy, carboxyl, ester group, nitro, amino and cyano, and n is 1-20; and the spatial configurations of the carbons at positions 2,3, 4 and 6 are all 2R, 3S, 4R and 6S, wherein when R is hydrogen, n is not 1 or 4; when R is hydroxy, n is not 2; when R is phenyl, n is not 1.
Further, in the compound shown in the formula I, R is any one of hydrogen, vinyl, ethynyl, aryl, hydroxyl, alkoxy and amino.
Still further, the aryl group may be phenyl, indol-3-yl, pyrrol-2-yl, furan-2-yl, thiophen-2-yl, partially or fully substituted phenyl, wherein the substituents in the partially or fully substituted phenyl group are indol-3-yl, pyrrol-2-yl, furan-2-yl, thiophen-2-yl, fluoro, chloro, bromo, iodo, hydroxy, methoxy, nitro, carboxy, cyano, amino, N-dimethylamino, phenyl, cyclohexyl, tert-butyl, C1-4Straight chain alkyl, C1-4Straight-chain alkylamino radical, C1-4At least one of a linear chain alkoxycarbonyl group;
preferably phenyl, partially or fully substituted phenyl, wherein the substituent of the partially or fully substituted phenyl is fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, nitro, carboxyl, cyano, amino, phenyl, cyclohexyl, tert-butyl, C1-4At least one linear alkyl group.
Still further, the halogen atom is: fluorine, chlorine, bromine, iodine; the alkoxy is: methoxy, ethoxy, propoxy, butoxy, tert-butoxy, benzyloxy.
In a second aspect, the present invention provides a process for the preparation of a compound of the invention, comprising the steps of:
(1) preparation of intermediate (III)
In the presence of a catalyst and a reducing agent, mixing a compound shown as a formula (II-1) and a compound shown as a formula (II-2) in a solvent and inert gas atmosphere, and then carrying out reductive amination reaction to obtain an intermediate (III);
(2) preparation of Compounds of formula (I)
In a solvent, under the action of acid, the intermediate (III) is subjected to a deprotection reaction to obtain the compound shown in the formula (I),
in a third aspect, the present invention provides a further process for the preparation of a compound of the invention, comprising the steps of:
(A) preparation of intermediate (III)
In a solvent, under the action of alkali, mixing a compound shown as a formula (II-1) and a halide shown as a formula (II-3) and then carrying out nucleophilic substitution reaction to obtain an intermediate (III);
wherein, X is chlorine, bromine or iodine;
(B) preparation of Compounds of formula (I)
In a solvent, under the action of acid, carrying out a protecting group removing reaction on the intermediate (III) to obtain a compound shown as a formula (I);
salts or hydrates of any of the compounds of formula I described above are also within the scope of the present invention. The salt is a pharmaceutically acceptable salt.
In a fourth aspect, the present invention provides a glycosidase inhibitor comprising the above compound, a salt thereof, or a hydrate thereof as an active ingredient, wherein the glycosidase is α -glucosidase, β -glucosidase, α -galactosidase, β -galactosidase, α -mannosidase, β -mannosidase, α -L-fucosidase, trehalase, amyloglucosidase, α -L-rhamnosidase, or β -glucuronidase.
In a fifth aspect, the present invention provides a use of the above-mentioned compound, a salt or hydrate thereof, or a hydrate of the salt as an active ingredient for the preparation of a medicament for the prevention and/or treatment of at least one of the following glycosidase-related diseases: 1) diabetes mellitus; 2) gaucher's disease; 3) a tumor; 4) viral infection, wherein the glycosidase is alpha-glucosidase, beta-glucosidase, alpha-galactosidase, beta-galactosidase, alpha-mannosidase, beta-mannosidase, alpha-L-fucosidase, amyloglucosidase, alpha-L-rhamnosidase or beta-glucuronidase.
The compound is an N-alkylated polyhydroxy pyrrolidine compound, improves DIM molecules (1, 4-dioxy-l, 4-imino-alpha-mannitol), introduces an alkyl chain with better lipophilicity on an N atom in the molecule, greatly improves the liposolubility of the DIM molecules, and is suitable for preparing oral medicaments.
The N-alkylated polyhydroxy pyrrolidine compound provided by the invention has a higher inhibition effect on different glycosidases, shows high selectivity, and can be used as an active ingredient for preparing various glycosidase-related medicines.
Detailed Description
The endpoints of the ranges and any values disclosed herein are not limited to the precise range or value, and such ranges or values should be understood to encompass values close to those ranges or values. For ranges of values, between the endpoints of each of the ranges and the individual points, and between the individual points may be combined with each other to give one or more new ranges of values, and these ranges of values should be considered as specifically disclosed herein.
In a first aspect, the present invention provides a compound having the structure shown in formula (I):
wherein, R is any one of hydrogen, aryl, hydroxyl, halogen atom, vinyl, ethynyl, alkoxy, carboxyl, ester group, nitro, amino and cyano, and n is 1-20; and the spatial configurations of the carbons at positions 2,3, 4 and 6 are all 2R, 3S, 4R and 6S, wherein when R is hydrogen, n is not 1 or 4; when R is hydroxy, n is not 2; when R is phenyl, n is not 1.
According to the present invention, the terminal group R in the structure of the compound may further be any one of hydrogen, vinyl, ethynyl, aryl, hydroxyl, alkoxy, and amino; preferably any of hydrogen, vinyl, aryl and hydroxyl.
According to the invention, the value of n in formula (I) can be determined by the choice of the end group R. Preferably, when R is hydrogen, n ═ 2,3, 5-20; preferably, when R is hydroxy, n is 3-20.
According to the invention, the aryl group is: phenyl, indol-3-yl, pyrrol-2-yl, furan-2-yl, thiophen-2-yl, partially or fully substituted phenyl, wherein the substituents in said partially or fully substituted phenyl are indol-3-yl, pyrrol-2-yl, furan-2-yl, thiophen-2-yl, fluoro, chloro, bromo, iodo, hydroxy, methoxy, nitro, carboxy, cyano, amino, N-dimethylamino, phenyl, cyclohexyl, tert-butyl, C1-4Straight chain alkyl, C1-4Straight-chain alkylamino radical, C1-4At least one of linear alkoxycarbonyl groups; preferably phenyl, partially or fully substituted phenyl, wherein the substituent of the partially or fully substituted phenyl is fluorine, chlorine, bromine, iodine, hydroxyl, methoxy, nitro, carboxyl, cyano, amino, phenyl, cyclohexyl, tert-butyl, C1-4At least one linear alkyl group.
The halogen atoms are: fluorine, chlorine, bromine, iodine; the alkoxy is: methoxy, ethoxy, propoxy, butoxy, tert-butoxy, benzyloxy.
Preferably, R is any one of hydrogen, vinyl, phenyl and hydroxyl.
According to the present invention, preferably, the compound is any one of compounds represented by the following formulae (I-1) to (I-29):
the salt or hydrate of any compound shown as the formula I is also within the protection scope of the invention, and the salt is pharmaceutically acceptable salt.
In a second aspect, the present invention provides a process for the preparation of a compound of the invention, comprising the steps of:
(1) preparation of intermediate (III)
In the presence of a catalyst and a reducing agent, mixing a compound shown as a formula (II-1) and a compound shown as a formula (II-2) in a solvent and inert gas atmosphere, and then carrying out reductive amination reaction to obtain an intermediate (III);
(2) preparation of Compounds of formula (I)
In a solvent, under the action of acid, the intermediate (III) is subjected to a deprotection reaction to obtain the compound shown in the formula (I),
in the present invention, the ratio of the amount of the compound represented by the formula (II-2) to the compound represented by the formula (II-1) is more than 1, and preferably, the ratio of the amount of the compound represented by the formula (II-2) to the amount of the compound represented by the formula (II-1) is 3: 1. The dosage of the catalyst is 1 to 50 percent of that of the compound shown in the formula (II-1), preferably 10 to 30 percent; the ratio of the amount of the reducing agent to the amount of the compound represented by the formula (II-1) is more than 1, and preferably, the ratio of the amount of the reducing agent to the amount of the compound represented by the formula (II-1) is 5-10:1
In the present invention, the compound represented by the formula (II-1) can be prepared by the following specific method:
the preparation method comprises the following steps:
dissolving a compound II-8 (2.2g,9.1mmol) in 15mL of anhydrous ether under the condition of ice-water bath, adding tert-butyl hypochlorite (1.23mL,10.9mmol), reacting for 30 minutes, maintaining the condition of ice-water bath, dropwise adding DBU (1.77mL, 11.8mmol), gradually raising the temperature to room temperature after dropwise adding, continuing to react for 1 hour under the condition of room temperature, wherein TCL shows that the reaction is complete, filtering to remove salts generated by the reaction, evaporating the solvent under reduced pressure, and quickly separating by column chromatography to obtain an intermediate II-9 which is light yellow syrup and has the yield of 2.1 g: 97 percent. δ H (400 MHz; CDCl3)5.15(1H, d, J ═ 5.8Hz),4.87 (1H, t, J ═ 6.2Hz),4.76(1H, t, J ═ 5.1Hz),4.30-4.24(2H, m),4.07-3.94(2H, m),1.43(3H, s),1.42(3H, s),1.38(3H, s),1.36(3H, s); Δ C (100 MHz; CDCl3)174.9,112.0,110.0,85.5,77.7, 73.4,67.3,65.4,26.8,26.3,25.39, 25.36.
Dissolving compound II-9 (3.37g,13.9mmol) in 30mL of anhydrous methanol under ice-water bath conditions, adding sodium borohydride (1.6g,42.0mmol), gradually heating to room temperature from ice-water bath, reacting at room temperature for 1 hour, TLC shows reaction completion, adding saturated aqueous ammonium chloride solution to quench the reaction, removing the solvent under reduced pressure, adding 500mL of water, extracting three times with ethyl acetate (500 mL. times.3), collecting the concentrated organic phase, and separating by column chromatography to obtain 2,3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol formula (II-1), (dr >99:1) as colorless transparent syrup, 3.19 g, yield: 94 percent. δ H (400 MHz; CDCl3)4.66(2H, ddd, J ═ 14.3Hz,3.8Hz,5.5Hz),4.26-4.21(1H, m),4.09 (1H, dd, J ═ 8.4Hz,6.2Hz),3.99(1H, dd, J ═ 8.4Hz,5.5Hz),3.09(1H, d, J ═ 13.0Hz),2.69 (1H, dd, J ═ 8.2Hz,3.7Hz),2.62(1H, dd, J ═ 13.0Hz,3.7Hz),1.45(3H, s),1.42(3H, s),1.38(3H, s),1.32(3H, s); Δ C (100 MHz; CDCl3)110.7,108.9,81.6,80.7,73.9,67.7,66.4,53.3, 26.9,25.7,25.4, 23.8.
In the present invention, the above-mentioned compound II-8 can be prepared by a method described in (a) J.Grant.Buchanan, K.W.Lumbard, R.J.Sturgeon, D.K.Thompson and R.H.Wightman, J Chem Soc,1990, 699-706; (b) A.Vasella, HeIvChimacta,1977,60, 1273-1295; (C) G.W.J.Fleet, J.C.son, D.S.C.Green, I.C.D.Beo and B.Wincher, Tetrahedron,1988,44, 2649-55; (d) H.Setoi, H.Kayari, H.Takeno and M Hashimoto, Schm rm Bucharm, 1987, 3935, 4095F, C.Layakiri, J.R.R.R.R.J.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.J.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.J.R.R.R.R.R.R.R.R.R.R.R.R.R.C.54. is described in detail, and R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.R.S.S.S.S.R.R.S.R.R.S.S.S.S.S.R.R.S.S.S.S.S.S.S.S.S.S.S.R.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.47.A.S.S.S.S.S.S.A.A. A. A.A.A.S.A.S.S.A.A.S.A.S.S.S.S.S.S.A.S.S.S.S.S.S.S.S.S.S.S.S.S.A.S.S.S.A. A. A.S.S.S.A.S.S.A.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.S.and.E.S.S.S.S.S.S.E.E.E.E.E.E.S.S.S.S.S.S.S.S.S.E.S.S.S.S.S.S.S.S.S.
The intermediate (II-8) can be synthesized according to the following process:
the preparation method comprises the following steps:
d-mannose (II-4) (100.0g,555.4mmol) is dissolved in 1000mL of acetone at room temperature, a catalytic amount of p-toluenesulfonic acid monohydrate (1.0g,5.3mmol) is added, 2-dimethoxypropane (150.2mL,1.2 mol) is added, the reaction is stirred for 3 hours under the condition, TLC shows that the raw materials disappear, the reaction is completed, sodium bicarbonate is added to quench the reaction, the solvent is neutralized to neutrality, inorganic salts are removed by filtration, and the solvent is evaporated to dryness to obtain a white solid which is the crude product 2,3:5, 6-O-diacetone-D-mannose (II-5) in the first step.
The crude product II-5 (calculated as 555.4 mol) was dissolved in 800mL of anhydrous methanol, followed by the sequential addition of triethylamine (116.6 mL,833.1mmol) and hydroxylamine hydrochloride (43.3g,666.5mmol), the reaction flask was placed in an oil bath, and when heating and refluxing were carried out for 6 hours, TCL showed the disappearance of the starting material, completion of the reaction, stoppage of the reaction, cooling to room temperature, evaporation of methanol and triethylamine under reduced pressure, addition of 500mL of water, extraction with ethyl acetate carried out three times (500 mL. times.3), and collection of the concentrated organic phase gave the crude product 2,3:5, 6-O-diacetone-alpha-D-mannoxime (II-6).
Dissolving the crude product II-6 (calculated by 555.4mmol) in 500mL pyridine, cooling to-20 ℃, dropwise adding methanesulfonyl chloride (107.5mL,1.4mol), reacting at-20 ℃ for 1 hour after dropwise adding, then gradually raising to room temperature, continuing to react for 10 hours, TLC shows that the reaction is complete, stopping the reaction, evaporating pyridine under reduced pressure, adding 500mL water, extracting with ethyl acetate for three times (500mL multiplied by 3), collecting a concentrated organic phase, and separating by column chromatography to obtain a white needle-like solid formula (II-7), 109.8g, yield: 59 percent.
Mp:80-81℃；δH(500MHz；CDCl3)4.91(1H,d,J＝4.7Hz),4.82(1H,t,J＝9.0Hz), 4.30-4.27(2H,m),4.14(1H,dd,J＝9.0Hz,6.7Hz),4.11-4.06(1H,m),3.15(3H,s),1.62(3H, s),1.49(3H,s),1.42(3H,s),1.36(3H,s)；δC(125MHz；CDCl3)116.6,112.0,111.6,80.8,77.8, 74.1 67.7,66.6,38.9,26.9,26.2,25.6,25.4。
Dissolving the product II-7 (3.35g,10.0mmol) in 30mL of anhydrous methanol under the ice-water bath condition, adding cobalt dichloride hexahydrate (4.76g,20.0mmol), fully stirring for 30 minutes, then adding sodium borohydride (3.8g,100.0mmol), gradually raising the temperature to room temperature, reacting at room temperature for 10 hours, TLC (TLC) shows that the reaction is complete, adding saturated ammonium chloride solution to quench the reaction, evaporating the solvent under reduced pressure, adding 50mL of water, extracting with ethyl acetate for three times (50mL multiplied by 3), collecting the concentrated organic phase, and separating by column chromatography to obtain 1, 4-dideoxy-2, 3:5, 6-diacetone-1, 4-imino-D-talitol (II-8), 2.2g, yield: 91 percent.
Mp:58-59℃；δH(500MHz；CDCl3)4.72(1H,ddd,J＝5.5Hz,4.1Hz,1.3Hz),4.47(1H, dd,J＝5.8Hz,1.4Hz),4.07(1H,dd,J＝11.7Hz,6.3Hz),4.02(1H,dd,J＝7.7Hz,6.4Hz),3.84 (1H,t,J＝7.5Hz),3.15(1H,dd,J＝5.7Hz,1.1Hz),3.09-3.02(2H,m),2.32(1H,br s),1.47 (3H,s),1.41(3H,s),1.33(3H,s),1.31(3H,s)；δC(125MHz；CDCl3)111.5,109.4,84.0,82.2, 76.0,66.83,66.81,53.2,26.48,26.46,25.3,24.2。
In the invention, the catalyst used in the reductive amination reaction is Rany-nickel, palladium carbon with the palladium content of 0.5-30 percent and PtO2At least one of; the reducing agent is at least one of hydrogen, sodium borohydride, sodium cyanoborohydride, lithium borohydride and sodium triacetoxyborohydride.
In the present invention, the reductive amination reaction temperature may be from-40 ℃ to 80 ℃, preferably from 0 ℃ to 30 ℃; the deprotection reaction temperature may be from-40 ℃ to 80 ℃, preferably from 10 ℃ to 30 ℃.
In the present invention, the inert gas atmosphere is nitrogen, helium, argon, preferably argon.
In the present invention, the solvent is a kind of solvent that is conventional in the art, specifically, the solvent is at least one of dichloromethane, chloroform, tetrahydrofuran, diethyl ether, ethyl acetate, water, dioxane, methanol, ethanol, acetonitrile, formamide or N, N-dimethylformamide, and preferably, the solvent is methanol.
In the invention, the acid is at least one of inorganic acid, organic acid or lewis acid, preferably, the inorganic acid is at least one of hydrochloric acid, hydrofluoric acid and sulfuric acid; the organic acid is at least one of acetic acid, p-toluenesulfonic acid, methanesulfonic acid and trifluoroacetic acid; the Lewis acid is at least one of titanium tetrachloride, stannic chloride, bismuth trichloride or zinc bromide.
In a third aspect, the present invention provides a further process for the preparation of a compound of the invention, comprising the steps of:
(A) preparation of intermediate (III)
In a solvent, under the action of alkali, mixing a compound shown as a formula (II-1) and a halide shown as a formula (II-3), and carrying out nucleophilic substitution reaction to obtain an intermediate (III);
wherein, X is chlorine, bromine or iodine;
(B) preparation of Compounds of formula (I)
In a solvent, under the action of acid, carrying out a protecting group removing reaction on the intermediate (III) to obtain a compound shown as a formula (I);
in the present invention, the amount ratio of the compound represented by the formula (II-3) to the halogenated compound represented by the formula (II-1) is more than 1, and preferably the amount ratio of the compound represented by the formula (II-3) to the compound represented by the formula (II-1) is 1.2: 1.
In the present invention, the nucleophilic substitution reaction temperature is-40 ℃ to 100 ℃, preferably 30 ℃ to 80 ℃; the reaction temperature for removing the protecting group is-40 ℃ to 80 ℃, preferably 10 ℃ to 30 ℃.
In the present invention, the solvent is a kind of solvent that is conventional in the art, specifically, the solvent is at least one of dichloromethane, chloroform, tetrahydrofuran, diethyl ether, ethyl acetate, water, dioxane, methanol, ethanol, acetonitrile, formamide, and N, N-dimethylformamide, and preferably, the solvent is methanol.
In the present invention, the base is an organic base and/or an inorganic base, preferably, the organic base is at least one of diethylamine, triethylamine, diisopropylamine, diisopropylethylamine, pyridine, and 2,4, 6-trimethylpyridine; the inorganic base is at least one of sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, sodium hydroxide, potassium hydroxide and sodium hydride.
In the present invention, the acid is at least one of an inorganic acid, an organic acid, and a lewis acid, and preferably, the inorganic acid is at least one of hydrochloric acid, hydrofluoric acid, and sulfuric acid; the organic acid is at least one of acetic acid, p-toluenesulfonic acid, methanesulfonic acid and trifluoroacetic acid; the Lewis acid is at least one of titanium tetrachloride, stannic chloride, bismuth trichloride and zinc bromide.
In a fourth aspect, the present invention provides a glycosidase inhibitor comprising the above compound, a salt thereof, or a hydrate thereof as an active ingredient, wherein the glycosidase is α -glucosidase, β -glucosidase, α -galactosidase, β -galactosidase, α -mannosidase, β -mannosidase, α -L-fucosidase, trehalase, amyloglucosidase, α -L-rhamnosidase, or β -glucuronidase.
In a fifth aspect, the present invention provides a use of the above-mentioned compound, a salt or hydrate thereof, or a hydrate of the salt as an active ingredient for the preparation of a medicament for the prevention and/or treatment of at least one of the following glycosidase-related diseases: 1) Diabetes mellitus; 2) gaucher's disease; 3) a tumor; 4) viral infection, wherein the glycosidase is alpha-glucosidase, beta-glucosidase, alpha-galactosidase, beta-galactosidase, alpha-mannosidase, beta-mannosidase, alpha-L-fucosidase, amyloglucosidase, alpha-L-rhamnosidase or beta-glucuronidase.
The present invention will be described in detail below by way of examples. In the following examples, the structures of the substances were determined by nuclear magnetic methods, and the specific operating conditions of the nuclear magnetic tests were:
in the following examples, unless otherwise specified, all experimental methods used were conventional methods; the materials, reagents, etc. used are commercially available.
The present invention will be further described with reference to the following examples, but the present invention is not limited to the following examples.
Example 1 preparation of N-ethyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-1).
The preparation method comprises the following steps:
dissolving compound II-1 (100mg,0.41mmol) in 15mL of methanol, adding acetaldehyde water solution (0.14mL, 1.23mmol), adding 10mg of 10% palladium carbon under argon atmosphere, replacing argon with hydrogen, stirring overnight at room temperature under hydrogen atmosphere, TLC indicating reactionAfter completion, the reaction was stopped, palladium on carbon was removed by filtration, the filtrate was concentrated and subjected to column chromatography to obtain N-ethyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (iii-1) as a pale yellow syrup, 99.5mg, yield: 89 percent. DeltaH(500MHz；CDCl3)4.60-4.56(2H,m),4.46(1H,td,J＝7.5Hz,2.0Hz,), 4.19(1H,t,J＝7.8Hz),3.99(1H,t,J＝7.5Hz),3.26(1H,d,J＝11.1Hz),3.11(1H,dq,J＝ 12.4Hz,7.5Hz)2.62(1H,d,J＝2.3Hz),2.15-2.08(2H,m),1.45(3H,s),1.43(3H,s),1.33 (3H,s),1.28(3H,s),1.04(1H,t,J＝7.5Hz)；δC(125MHz；CDCl3)110.9,107.1,81.2,77.6, 75.2,67.6,65.8,58.5,47.8,26.2,25.8,24.7,24.0,12.5.
Intermediate III-1 (20mg,0.09mmol) was dissolved in 10mL of methanol, 1mL of 6N hydrochloric acid was added, the reaction was stirred at room temperature for 1 hour, the reaction was stopped, and the solvent was evaporated under reduced pressure to give 16.7 mg of N-ethyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-1) as a white solid, in yield: 100 percent. Mp:142-143 deg.C; deltaH(500MHz；D2O)4.57-4.51 (2H,m),4.22(1H,dd,J＝11.0Hz,5.0Hz),3.83(2H,m),3.65(1H,t,J＝4.1Hz),3.59(3H,m) 3.16(1H,dq,J＝13.0Hz,7.3Hz)1.35(1H,t,J＝7.3Hz)；δC(125MHz；D2O)70.8,68.5,68.1, 67.3,62.5,54.6,49.3,9.3.
Example 2 preparation of N-propyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-2).
Referring to the synthesis procedure in example 1, starting from compound ii-1 (120mg,0.49mmol) and propionaldehyde (86mg,1.47 mmol), 131 mg of intermediate N-propyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (iii-2) was obtained in yield: 81 percent. Pale yellow syrup, deltaH(400MHz；CDCl3)4.60-4.54(2H,m,),4.46(1H, td,J＝7.2Hz,1.6Hz),4.21(1H,t,J＝8.0Hz),3.98(1H,t,J＝7.6Hz),3.25(1H,d,J＝10.8 Hz),3.05-2.98(1H,m)2.61(1H,d,J＝2.8Hz),2.07-1.99(2H,m),1.51-1.42(8H,m),1.32 (3H,s),1.27(3H,s),0.90(1H,t,J＝7.4Hz)；δC(100MHz；CDCl3)110.0,107.1,81.1,77.7, 75.3,67.9,65.7,59.1,56.0,26.2,25.9,24.9,24.0,20.9,11.8。
Intermediate III-2 (30.0mg,0.10mmol) was stripped off with hydrochloric acidProtecting group to give N-propyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-2) as a pale yellow syrup, 25.3 mg, yield: 99 percent. DeltaH(400MHz；D2O) 4.55-4.51(2H,m),4.23-4.22(1H,m),3.88-3.80(2H,m),3.66(1H,s),3.57-3.59(2H,m) 3.40-3.33(1H,m),3.10-3.03(1H,m),1.77-1.75(2H,m),0.98(1H,t,J＝7.2Hz)；δC(100MHz； D2O)70.7,68.8,68.6,67.3,62.6,55.0,55.4,18.1,10.1。
Example 3 preparation of N-pentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-3).
Referring to the synthesis procedure in example 1, compound ii-1 (100.0mg,0.41mmol) and N-valeraldehyde (106mg, 12.3mmol) gave intermediate N-pentyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (iii-3) as a colorless syrup, 108 mg, yield: 84 percent. DeltaH(400MHz；CDCl3)4.59-4.54(2H,m),4.46(1H,td,J＝ 7.2Hz,1.6Hz),4.19(1H,t,J＝7.6Hz),3.98(1H,t,J＝7.6Hz),3.25(1H,d,J＝11.0Hz), 3.09-3.01(1H,m),2.59(1H,d,J＝2.7Hz),2.06-1.97(2H,m),1.46-1.21(18H,m),0.88(3H,t, J＝7.2Hz)；δC(100MHz；CDCl3)111.0,107.1,81.1,77.7,75.3,68.0,65.7,59.1,54.2,29.6, 27.4,26.3,25.9,24.9,24.0,22.6,14.1。
Intermediate III-3 (16.0mg,0.05mmol) was deprotected under hydrochloric acid to give N-pentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-3) as a pale yellow syrup, 13.6 mg, yield: 99 percent. DeltaH(400MHz；D2O) 4.53-4.47(2H,m),4.18(1H,dd,J＝10.4Hz,5.2Hz),3.86-3.78(2H,m),3.53(1H,s), 3.45-3.44(2H,m),3.32-3.24(1H,m),3.02-2.95(1H,m),1.71-1.65(2H,m),1.36-1.31(4H,m), 0.89(3H,t,J＝7.2Hz)；δC(100MHz；D2O)71.0,68.8,68.4,67.8,62.7,55.4,54.8,28.0,24.4, 21.5,13.0。
Example 4 preparation of N-hexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-4).
Referring to the synthesis method in example 1, compound II-1 (59.0mg,0.24mmol) and N-hexanal (76.1mg, 0.72mmol) are used as raw materials, and catalytic hydrogenation is carried out on 10% palladium carbon to obtain intermediate N-hexyl-2, 3:5, 6-diacetone-1, 4-dideoxy1, 4-imino-D-mannitol (iii-4) as a colorless syrup, 74.6 mg, yield: 94 percent. DeltaH(400MHz；CDCl3) 4.60-4.55(2H,m),4.46(1H,td,J＝7.3Hz,1.6Hz),4.20(1H,t,J＝7.6Hz),3.98(1H,t,J＝7.6 Hz),3.26(1H,d,J＝11.0Hz),3.09-3.02(1H,m),2.59(1H,d,J＝2.6Hz),2.07-1.98(2H,m), 1.44-1.27(20H,m),0.88(3H,t,J＝6.4Hz)；δC(100MHz；CDCl3)111.0,107.1,81.1,77.7, 75.3,68.0,65.8,59.1,54.2,31.8,27.7,27.0,26.3,25.9,24.9,24.0,22.6,14.0。
Intermediate III-4 (27.0mg,0.08mmol) was deprotected under hydrochloric acid to give N-hexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-4) as a pale yellow syrup, 23.4 mg, yield: 100 percent. DeltaH(500MHz；D2O) 4.57-4.51(2H,m),4.22(1H,dd,J＝9.0Hz,4.5Hz),3.84(2H,qd,J＝11.9Hz,6.2Hz),3.66 (1H,s),3.55(2H,d,J＝7.4Hz),3.42-3.35(1H,m),3.12-3.07(1H,m,),1.78-1.69(2H,m), 1.39-1.32(6H,m),0.87(3H,t,J＝5.5Hz)；δC(125MHz；D2O)70.7,68.7,68.6,67.2,62.5, 55.3,54.5,30.3,25.3,24.2,21.6,13.1。
Example 5 preparation of N-heptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-5).
Referring to the synthesis procedure in example 1, starting from compound ii-1 (142.0mg,0.58mmol) and N-heptanal (198.6mg, 1.74mmol), catalytic hydrogenation was carried out using 10% palladium on carbon to give the intermediate N-heptyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (iii-5) as a colorless syrup in 140.1 mg yield: 71 percent. DeltaH(500MHz；CDCl3) 4.58-4.54(2H,m),4.46(1H,t,J＝7.5Hz),4.18(1H,t,J＝7.5Hz),3.98(1H,t,J＝7.5Hz,H1), 3.25(1H,d,J＝11.0Hz),3.08-3.02(1H,m),2.59(1H,d,J＝3.5Hz),2.06-1.98(2H,m), 1.43-1.27(22H,m),0.87(3H,t,J＝6.3Hz)；δC(125MHz；CDCl3)111.0,107.1,81.1,77.7, 75.3,68.0,65.8,59.1,54.3,31.9,29.3,27.7,27.4,26,3,25.9,24.9,24.0,22.7,14.1。
Intermediate III-5 (35.0mg,0.10mmol) was deprotected under hydrochloric acid to give N-heptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-5) as a pale yellow syrup, 30.5 mg, yield:100％。δH(400MHz；D2O) 4.59-4.51(2H,m),4.23(1H,dd,J＝10.3Hz,5.1Hz),3.88(2H,qd,J＝12.0Hz,6.0Hz,5.2Hz), 3.67(1H,t,J＝4.0Hz),3.56(2H,d,J＝7.6Hz),3.44-3.37(1H,m),3.15-3.07(1H,m), 1.80-1.71(2H,m),1.37-1.30(8H,m),0.88(3H,t,J＝7.2Hz)；δC(100MHz；D2O)70.7,68.8, 68.6,67.3,62.6,55.4,54.6,30.7,27.8,24.3,21.8,13.3。
example 6 preparation of N-octyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-6).
Referring to the synthesis method in example 1, starting from compound ii-1 (96.0mg,0.23mmol) and N-octanal (88.5mg, 0.69mmol), catalytic hydrogenation was carried out using 10% palladium on carbon to obtain intermediate N-octyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (iii-6) as a colorless syrup in 64.6 mg yield: 79 percent. DeltaH(500MHz；CDCl3) 4.59-4.55(2H,m),4.46(1H,td,J＝7.5Hz,1.5Hz),4.19(1H,t,J＝7.5Hz),3.98(1H,t,J＝ 7.5Hz),3.25(1H,d,J＝11.0Hz),3.08-3.02(1H,m),2.59(1H,d,J＝3.0Hz),2.06-1.98(2H, m),1.47-1.27(24H,m),0.87(3H,t,J＝6.5Hz)；δC(125MHz；CDCl3)111.0,107.1,81.1, 77.71,75.3,68.0,65.8,59.1,54.3,31.9,29.6,29.3,27.8,27.4,26.3,25.87,24.9,24.1,22.7, 14.1。
Intermediate III-6 (25.0mg,0.07mmol) was deprotected under hydrochloric acid to give N-octyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-6) as a pale yellow syrup, 21.9 mg, yield: 100 percent. DeltaH(400MHz；D2O) 4.58-4.50(2H,m),4.22(1H,dd,J＝10.3Hz,5.1Hz),3.84(2H,qd,J＝11.9Hz,6.1Hz,5.0Hz), 3.66(1H,t,J＝4.2Hz),3.56(2H,d,J＝7.4Hz),3.44-3.36(1H,m),3.13-3.06(1H,m), 1.79-1.67(2H,m),1.36-1.28(10H,m),0.86(3H,t,J＝6.4Hz)；δC(100MHz；D2O)70.7,68.7, 68.6,67.3,62.5,55.3,54.6,30.9,28.1,28.1,25.7,24.3,21.9,13.4。
Example 7 preparation of N-nonyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-7).
Referring to the synthesis method in example 1, starting from compound II-1 (60.0mg,0.16mmol) and n-nonanal (68.3mg, 0.68mmol), 10% is passedPalladium on carbon catalytic hydrogenation gave (ii-1) intermediate N-nonyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (iii-7) as a colourless syrup, 41.7 mg, yield: 71 percent. DeltaH(500MHz； CDCl3)4.59-4.55(2H,m),4.46(1H,t,J＝7.0Hz),4.19(1H,t,J＝7.5Hz),3.98(1H,t,J＝ 7.5Hz),3.25(1H,d,J＝11.5Hz),3.08-3.02(1H,m),2.59(1H,d,J＝3.0Hz),2.06-1.98(2H, m),1.43-1.25(24H,m),0.87(3H,t,J＝6.5Hz)；δC(125MHz；CDCl3)111.0,107.1,81.1,77.7, 75.3,68.0,65.7,59.1,54.3,31.9,29.6,29.3,27.7,27.4,26.3,25.9,24.9,24.1,22.7,14.1。
Intermediate III-7 (30.1mg,0.08mmol) was deprotected under hydrochloric acid to give N-nonyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-7) as a pale yellow syrup, 26.4 mg, yield: 100 percent. DeltaH(400MHz；D2O) 4.53-4.50(2H,m),4.20(1H,m),3.82(2H,s),3.64(1H,s),3.53(2H,d,J＝6.7Hz),3.38-3.34 (1H,m),3.11-3.07(1H,m),1.73(2H,s),1.32-1.26(12H,m),0.84(3H,s)；δC(100MHz；D2O) 70.7,68.7,68.5,67.2,62.5,55.3,54.5,31.0,28.3,28.2,28.1,25.6,24.2,21.9,13.3。
Example 8 preparation of N-allyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-8).
The preparation method comprises the following steps:
dissolving the compound II-1 (3.0g,12.3mmol) in 30mL of dry N, N-dimethylformamide, adding potassium carbonate (5.2g,37.1mmol) and 3-bromo-1-propene (3.0g,24.6mmol), heating to 65 ℃ under argon atmosphere, reacting overnight, TLC showing complete reaction, stopping reaction, adding 200mL of water, extracting three times with ethyl acetate (100 mL. times.3), collecting concentrated organic phase, and separating by column chromatography to obtain the intermediate N-allyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-8) as light yellow syrup with 3.0g and 87% yield. DeltaH(500MHz；CDCl3) 5.92-5.84(1H,m),5.17(1H,dd,J＝17.5Hz,1.5Hz),5.08(1H,d,J＝10.5Hz)4.58-4.54(2H, m),4.47(1H,td,J＝7.5Hz,2.0Hz),4.22(1H,t,J＝8.0Hz),4.00(1H,t,J＝7.5Hz),3.77(1H, ddt,J＝17.5Hz,6.5Hz,2.0Hz),3.20(1H,d,J＝14.0Hz),3.76-3.71(2H,m),2.13(1H,dd,J＝ 14Hz,5.5Hz),1.45(3H,s),1.43(3H,s),1.33(3H,s),1.27(3H,s)；δC(125MHz；CDCl3) 135.2,116.7,111.0,107.1,81.0,77.5,75.2,66.8,65.7,58.6,56.5,26.2,25.8,24.6,23.9。
Intermediate III-8 (13.5mg,0.05mmol) was dissolved in 10mL of methanol, 1mL of 6N hydrochloric acid was added, the reaction was stirred at room temperature for 1 hour, the reaction was stopped, and the solvent was evaporated under reduced pressure to give N-allyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-8) as a pale yellow syrup, 11.4 mg, yield: 100 percent. DeltaH(400MHz；D2O)6.02-5.91(1H, m),5.66-5.60(2H,m),4.53-4.48(2H,m),4.22(1H,dd,J＝10.4Hz,5.1Hz),4.01(1H,dd,J＝ 13.2Hz,6.4Hz),3.87-3.68(4H,m),3.60-3.55(1H,m),3.46(1H,d,J＝12.1Hz,6.4Hz)； δC(100MHz；D2O)126.7,125.6,70.9,68.5,67.6,67.3,62.5,55.8,54.6。
Example 9 preparation of N-Enylbutyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-9).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was performed using compound II-1 (60.1mg,0.25mmol) and 4-bromo-1-butene (66.2mg,0.49mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-alkenylbutyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-9) as a colorless syrup in 63.1 mg at a yield of 86%. DeltaH(400MHz；CDCl3)5.81(1H,ddt,J＝17.0Hz,10.3Hz,6.5Hz),5.06-4.95(2H, m),4.60-4.55(2H,m),4.46(1H,td,J＝6.4Hz,1.6Hz),4.21(1H,t,J＝8.0Hz),3.98(1H,t,J ＝7.6Hz),3.27(1H,d,J＝10.8Hz),3.20-3.13(1H,m),2.67(1H,dd,J＝4.3Hz,1.1Hz), 2.24-2.11(4H,m),1.43(6H,s),1.32(3H,s),1.27(3H,s)；δC(100MHz；CDCl3)136.7,115.3, 111.1,107.1,81.0,77.7,75.3,67.6,65.7,59.1,53.3,31.9,26.2,25.8,24.8,24.0。
Removing the protecting group of the intermediate III-9 (40.0mg,0.08mmol) under the action of hydrochloric acid to obtain N-alkenyl butyl-1, 4-dideoxy-1, 4-imino-D-mannitol(I-9) was pale yellow syrup, 34.1 mg, yield: 100 percent. DeltaH(400MHz； D2O)5.83(1H,ddt,J＝17.1Hz,10.3Hz,6.7Hz),5.30-5.21(2H,m),4.59-4.52(2H,m),4.24 (1H,dd,J＝10.1Hz,4.9Hz),3.90(1H,dd,J＝11.9Hz,5.9Hz),3.83(1H,dd,11.8Hz,4.8 Hz),3.72(1H,t,J＝4.3Hz),3.59-3.51(3H,m),3.25-3.18(1H,m),2.61-2.49(2H,m)；δC(100 MHz；D2O)132.4,118.8,70.6,69.3,68.6,67.1,62.6,67.1,62.6,55.4,53.6,28.9。
Example 10 preparation of N-Enopentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-10).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was performed using compound II-1 (1.0g,4.11mmol) and 5-bromo-1-pentene (1.2g, 8.22mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-alkenylpentyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-10) as a colorless syrup, 0.91 g, 71% yield. DeltaH(400MHz；CDCl3)5.83(1H,ddt,J＝17.0Hz,10.3Hz,6.6Hz),5.03-4.92(2H,m), 4.60-4.55(2H,m),4.46(1H,td,J＝7.8Hz,1.7Hz),3.98(1H,t,J＝7.5Hz),3.98(1H,t,J＝ 7.6Hz),3.26(1H,d,J＝11.0Hz),3.20-3.13(1H,dt,J＝12.2Hz,8.5Hz),2.60(1H,d,J＝2.7Hz), 2.07-2.03(4H,m),1.60-1.55(2H,m),1.43(6H,s),1.32(3H,s),1.27(3H,s)；δC(100MHz； CDCl3)138.8,114.4,111.0,107.1,81.1,77.7,75.3,68.1,65.7,59.1,53.7,31.5,27.1,26.3, 25.9,24.8,24.0。
Intermediate III-10 (100.0mg,0.32mmol) was deprotected under hydrochloric acid to give N-alkenylpentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-10) as a pale yellow syrup, 85.0 mg, yield: 99 percent. DeltaH(400MHz； D2O)5.83(1H,m),5.14-5.06(2H,m),4.53-4.50(2H,m),4.20(1H,s),3.86-3.82(2H,m),3.65 (1H,s),3.56-3.54(2H,m),3.43-3.36(1H,m),3.13-3.06(1H,m),2.16-2.15(2H,m),1.86(2H, s)；δC(100MHz；D2O)137.0,116.0,70.7,68.8,68.6,67.2,62.5,55.4,53.9,29.8,23.5。
Example 11 preparation of N-alkenylhexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-11).
Reference exampleThe synthesis method 8 is characterized in that a compound II-1 (54.0mg,0.22mmol) and 6-bromo-1-hexene (71.8 mg,0.44mmol) are used as raw materials, and nucleophilic substitution reaction is carried out under the action of potassium carbonate to obtain an N-alkylated intermediate N-alkenyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-11) which is colorless syrup and has the yield of 40.0 mg. DeltaH(400MHz；CDCl3)5.83(1H,ddt,J＝17.0Hz,10.3Hz,6.6Hz),5.02-4.92(2H, m),4.59-4.55(2H,m),4.47(1H,t,J＝7.2Hz),3.20(1H,t,J＝7.7Hz),3.98(1H,t,J＝7.6Hz), 3.25(1H,d,J＝11.0Hz),3.20-3.13(1H,dt,J＝14.2Hz,8.3Hz),2.60(1H,d,J＝2.7Hz), 2.07-2.00(4H,m),1.47-1.35(10H,m),1.33(3H,s),1.27(3H,s)；δC(100MHz；CDCl3)139.0, 114.3,111.0,107.1,81.1,77.7,75.3,68.1,65.7,59.1,54.0,33.7,27.2,26.7,26.3,25.9,24.8, 23.9。
Intermediate III-11 (30.0mg,0.09mmol) was deprotected under hydrochloric acid to give N-alkenylhexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-11) as a pale yellow syrup, 25.9 mg, yield: 100 percent. DeltaH(400MHz； D2O)5.88(1H,ddt,J＝17.1Hz,10.3Hz,6.7Hz),5.11-5.03(2H,m),4.57-4.50(2H,m),4.22 (1H,dd,J＝10.2Hz,5Hz),3.88-3.79(2H,m),3.66(1H,t,J＝4.1Hz),3.56-3.54(2H,m), 3.45-3.35(1H,m),3.15-3.07(1H,m),2.12(2H,dd,J＝17Hz,6.8Hz),1.78-1.75(2H,m), 1.51-1.47(2H,m)；δC(100MHz；D2O)138.6,115.0,70.6,68.7,68.5,67.2,62.5,55.3,54.17, 3.19,24.8,23.6。
Example 12 preparation of N-alkenylheptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-12).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was carried out using compound II-1 (328.0mg,1.35mmol) and 7-bromo-1-heptene (471.8mg,2.70mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-alkenylheptyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-12) as a colorless syrup in 398.0 mg at a yield of 87%. DeltaH(400MHz；CDCl3)5.79(1H,ddt,J＝17.0Hz,10.2Hz,6.6Hz),5.00-4.90 (2H,m),4.59-4.54(2H,m),4.46(1H,t,J＝7.3Hz),4.18(1H,t,J＝7.8Hz),3.98(1H,t,J＝ 7.6Hz),3.25(1H,d,J＝11.0Hz),3.20-3.13(1H,dt,J＝12.0Hz,8.1Hz),2.59(1H,d,J＝2.4 Hz),2.06-1.98(4H,m),1.51-1.27(18H,m)；δC(100MHz；CDCl3)139.0,114.2,111.0,107.1, 81.1,77.7,75.3,68.0,65.7,59.1,54.1,33.8,28.8,27.6,26.87,26.28,25.86,24.9,24.0。
Intermediate III-12 (22.0mg,0.06mmol) was deprotected under hydrochloric acid to give N-alkenylheptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-12) as a pale yellow syrup, 20.0 mg, yield: 100 percent. DeltaH(400MHz； D2O)5.93(1H,ddt,J＝17.1Hz,10.3Hz,6.7Hz),5.11-5.01(2H,m),4.60-4.53(2H,m),4.24 (1H,dd,J＝10.3Hz,5.0Hz),3.91-3.82(2H,m),3.68(1H,t,J＝4.1Hz),3.59-3.57(2H,m), 3.46-3.39(1H,m),3.16-3.09(1H,m),2.11(2H,dd,J＝13.4Hz,6.5Hz),1.80-1.74(2H,m), 1.53-1.39(2H,m)；δC(100MHz；D2O)139.6,114.5,70.7,68.8,68.6,67.3,62.6,55.4,54.5, 32.7,24.4,25.2,24.2。
Example 13 preparation of N-Endoctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-13).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was performed using compound II-1 (145.0mg,0.60mmol) and 8-bromo-1-octene (229.3mg,1.20mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-alkenyloctyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-13) as a colorless syrup, 134.8 mmol, 64% yield. DeltaH(400MHz；CDCl3)5.79(1H,ddt,J＝17.0Hz,10.2Hz,6.6Hz),5.00-4.90 (2H,m),4.59-4.54(2H,m),4.45(1H,td,J＝7.3Hz,1.6Hz),4.19(1H,t,J＝7.7Hz),3.97(1H, t,J＝7.5Hz),3.24(1H,d,J＝11.0Hz),3.20-3.13(1H,dt,J＝11.8Hz,8.1Hz),2.59(1H,d, J＝2.8Hz),2.06-1.98(4H,m),1.48-1.24(20H,m)；δC(100MHz；CDCl3)139.2,114.1,111.0, 107.1,81.1,77.7,75.3,68.0,65.7,59.1,54.2,33.8,29.1,28.9,27.7,27.2,26.3,25.9,24.9,24.0。
Intermediate III-13 (50.0mg,0.06mmol) was deprotected under the action of hydrochloric acid, and subjected to column chromatography to give N-alkenyloctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-13) as a pale yellow syrup, 28.8 mg, yield: 66 percent. DeltaH(400MHz；D2O)5.93(1H,ddt,J＝17.2Hz,10.3Hz,6.7Hz),5.11-5.00(2H,m), 4.59-4.52(2H,m),4.23(1H,dd,J＝10.4Hz,5.1Hz),3.90-3.81(2H,m),3.66(1H,t,J＝4.2 Hz),3.56-3.54(2H,m),3.43-3.36(1H,m),3.14-3.06(1H,m),2.11(2H,dd,J＝12.4Hz,7.8 Hz),1.82-1.71(2H,m),1.47-1.40(6H,m)；δC(100MHz；D2O)140.1,114.2,70.8,68.7,68.6, 67.4,62.6,55.4,54.6,32.9,27.7,27.6,25.5,24.3。
Example 14 preparation of N-Enonyi-1, 4-dideoxy-1, 4-imino-D-mannitol (I-14).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was carried out using compound II-1 (64.0mg,0.26mmol) and 9-bromo-1-nonene (108.7 mg,0.53mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-enamonyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-14) as a colorless syrup, 66.7 mg, 69% yield. DeltaH(400MHz；CDCl3)5.79(1H,ddt,J＝17.0Hz,10.2Hz,6.7Hz),5.00-4.90(2H, m),4.58-4.54(2H,m),4.45(1H,td,J＝7.3Hz,1.6Hz),4.18(1H,t,J＝7.8Hz),3.97(1H,t,J ＝7.5Hz),3.24(1H,d,J＝11.0Hz),3.05(1H,dt,J＝12.1Hz,8.0Hz),2.58(1H,d,J＝2.4Hz), 2.06-1.97(4H,m),1.43-1.26(22H,m)；δC(100MHz；CDCl3)139.2,114.1,111.0,107.1,81.1, 77.7,75.3,68.1,65.8,59.1,54.2,33.8,29.4,29.1,28.9,27.7,27.3,26.3,25.9,24.8,24.0。
Intermediate iii-14 (26.0mg,0.07mmol) was deprotected under the action of hydrochloric acid, and subjected to column chromatography to give N-alkenylnonyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-14) as a pale yellow syrup, 16.2 mg, yield: 71 percent. DeltaH(400MHz；D2O)5.95(1H,ddt,J＝17.1Hz,10.3Hz,6.7Hz),5.11-5.00(2H,m), 4.61-4.54(2H,m),4.25(1H,dd,J＝10.3Hz,5.1Hz),3.92-3.83(2H,m),3.69(1H,t,J＝4.2 Hz),3.59-3.58(2H,m),3.46-3.39(1H,m),3.17-3.10(1H,m),2.10(2H,dd,J＝13.4Hz,6.5 Hz),1.83-1.73(2H,m),1.54-1.29(8H,m)；δC(100MHz；D2O)140.4,114.1,70.8,68.8,68.6, 67.3,62.6,55.4,54.6,33.0,28.0,25.6,24.3。
Example 15 preparation of N-phenethyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-15).
Referring to the synthesis method in example 8, nucleophilic substitution reaction was performed using compound II-1 (110.0mg,0.45mmol) and 2-phenylbromide ethane (166.5mg,0.90mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-phenethyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-15) as a white solid in 116.1 mg, yield 74%. And Mp: 86-87 ℃; deltaH(400MHz；CDCl3)7.30-7.26(2H,m),7.23-7.17(2H,m), 4.64-4.57(2H,m),4.47(2H,td,J＝7.3Hz,1.4Hz),4.06(1H,t,J＝7.8Hz),3.93(1H,t,J＝ 7.5Hz),3.41-3.34(2H,m),2.80-2.77(2H,m),2.73(1H,d,J＝3.8Hz),2.40-2.34(1H,m),2.23 (1H,dd,J＝10.9Hz,4.6Hz),1.42(3H,s),1.41(3H,s),1.33(3H,s),1.29(3H,s)；δC(100MHz； CDCl3)140.6,128.8,128.2,125.9,111.1,107.1,81.0,77.7,75.2,67.4,65.6,59.2,55.5,34.1, 26.3,25.9,24.8,23.9。
Intermediate III-15 (22.0mg,0.06mmol) was deprotected under hydrochloric acid to give N-phenethyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-15) as a pale yellow syrup, 17.5 mg, yield: 100 percent. DeltaH(500MHz； D2O)7.44-7.41(2H,m),7.37-7.36(3H,m),4.59-4.55(1H,m),4.53-4.52(1H,m),4.22-4.21 (1H,m),3.86(1H,dd,J＝11.8Hz,6.8Hz),3.79(1H,dd,J＝11.8Hz,4.6Hz),3.72-3.58(4H, m),3.41-3.55(1H,m),3.18-3.07(2H,m)；δC(125MHz；D2O)136.0,129.1,128.8,127.4,70.5, 69.3,68.6,67.0,62.5,55.4,55.3,30.7。
Example 16 preparation of N-phenylpropyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-16).
Referring to the synthesis method in example 8, nucleophilic substitution reaction was performed using compound II-1 (110.0mg,0.45mmol) and 1-bromo-3-phenylpropane (179.2mg,0.90mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-phenylpropyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-16) as colorless syrup, 117.7 mg, yield 72%. DeltaH(400MHz；CDCl3)7.28-7.25(2H,m),7.19-7.14(3H,m),4.60-4.56(2H, m),4.45(2H,td,J＝7.3Hz,1.9Hz),4.16(1H,t,J＝7.8Hz),3.95(1H,t,J＝7.5Hz),3.29(1H, d,J＝10.9Hz),3.11(1H,m,dt,J＝12.2Hz,8.4Hz),2.75-2.68(1H,m),2.62-2.54(2H,m), 2.13-2.06(2H,m),1.85-1.73(2H,m),1.45(3H,s),1.36(3H,s),1.32(3H,s),1.28(3H,s)；δC (100MHz；CDCl3)142.4,128.4,128.3,125.7,111.0,107.1,81.1,77.7,75.3,68.1,65.8,59.1, 53.8,33.6,29.5,26.2,25.9,24.9,24.0。
Intermediate III-16 (30.0mg,0.08mmol) was deprotected under the action of hydrochloric acid to give N-phenylpropyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-16) as a pale yellow syrup, 26.3 mg, yield: 100 percent. DeltaH(400MHz； D2O)7.43-7.39(2H,m),7.34-7.32(3H,m),4.52-4.49(2H,m),4.17-4.14(1H,m),3.84-3.76 (2H,m),3.61(1H,s),3.57-3.48(2H,m),3.45-3.38(1H,m),3.41-3.55(1H,m),2.82-2.69(2H, m),2.14-2.06(2H,m)；δC(100MHz；D2O)140.5,128.9,128.5,126.6,70.7,68.8,68.6,67.2, 62.5,55.4,53.7,31.7,26.0。
Example 17 preparation of N-phenylbutyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-17).
Referring to the synthesis method in example 8, nucleophilic substitution reaction was performed using compound II-1 (190.0mg,0.78mmol) and 1-bromo-4-phenylbutane (332.5mg,1.56mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-phenylbutyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-17) as a colorless syrup, 225.8 mg, 77% yield. DeltaH(400MHz；CDCl3)7.29-7.25(2H,m),7.19-7.15(3H,m),4.59-4.55(2H, m),4.48(2H,td,J＝7.2Hz,1.3Hz),4.22(1H,t,J＝7.7Hz),3.99(1H,t,J＝7.6Hz),3.25(1H, d,J＝11.0Hz),3.12(1H,dt,J＝12.2Hz,8.4Hz),2.69-2.58(1H,m),2.08-2.02(2H,m), 1.77-1.47(4H,m),1.45-1.44(6H,m),1.33(3H,s),1.28(3H,s)；δC(100MHz；CDCl3)142.7, 128.4,128.3,125.6,111.0,107.1,81.1,77.7,75.3,68.1,65.7,59.1,54.0,35.8,29.1,27.4,26.3, 25.9,24.8,23.9。
Intermediate III-17 (50.0mg,0.13mmol) was deprotected under hydrochloric acid to give N-phenylbutyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-17) as a pale yellow syrup, 44.3 mg, yield: 99 percent. DeltaH(400MHz； D2O)7.40-7.36(2H,m),7.31-7.26(3H,m),4.44(2H,s),4.12-4.11(1H,m),3.78(2H,d,J＝5.2 Hz),3.42(1H,s),3.38-3.27(2H,m),3.22-3.20(1H,m),2.99-2.92(1H,m),2.68(2H,s),1.68 (4H,s)；δC(100MHz；D2O)142.3,128.7,128.6,126.1,71.1,68.9,68.3,68.1,62.7,55.4,54.7, 34.4,27.7,24.4。
Example 18 preparation of N-phenylpentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-18).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was performed using compound II-1 (145.0mg,0.60mmol) and 1-bromo-5-phenylpentane (271.2mg,1.20mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-phenylpentyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-18) as a colorless syrup in 169.5 mg at 73% yield. DeltaH(400MHz；CDCl3)7.27-7.24(2H,m),7.17-7.14(3H,m),4.59-4.54(2H, m),4.46(2H,td,J＝7.3Hz,1.6Hz),4.19(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.5Hz),3.25(1H, d,J＝11.0Hz),3.07(1H,m,dt,J＝11.7Hz,8.1Hz),2.62-2.58(3H,m),2.06-1.99(2H,m), 1.68-1.58(2H,m),1.54-1.27(16H,m)；δC(100MHz；CDCl3)142.8,128.4,128.2,125.6, 111.0,107.1,81.1,77.7,75.2,68.0,65.7,59.1,54.1,36.0,31.5,27.6,27.1,26.3,25.9,24.8, 24.0。
Intermediate III-18 (40.0mg,0.10mmol) was deprotected under hydrochloric acid to give N-phenylpentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-18) as a pale yellow syrup, 35.5 mg, yield: 100 percent. DeltaH(500MHz； D2O)7.39-7.36(2H,m),7.31-7.26(3H,m),4.54-4.49(2H,m),4.19(1H,dd,J＝10.5Hz,5.0 Hz),3.83(2H,ddd,J＝42.2Hz,11.9Hz,6.1Hz),3.62(1H,t,J＝4.1Hz),3.55-3.47(2H,m), 3.39-3.33(1H,m),3.08-3.02(1H,m),2.67(2H,t,J＝7.5Hz),1.81-1.72(2H,m),1.71-1.65(2H, m),1.45-1.33(2H,m)；δC(125MHz；D2O)142.9,128.6,125.9,70.7,68.7,68.6,67.2,62.5, 55.3,54.4,34.7,30.0,25.2,24.2。
Example 19 preparation of N-phenylhexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-19).
According to the synthesis method in example 8, compound II-1 (110.0mg, 0.4)5mmol) and 1-bromo-6-phenylhexane (216.1mg,0.90mmol) as raw materials, and nucleophilic substitution reaction is carried out under the action of potassium carbonate to obtain N-alkylated intermediate N-phenylhexyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-19) as colorless syrup, 147.8 mmol, with a yield of 81%. DeltaH(500MHz；CDCl3)7.28-7.25(2H,m),7.18-7.15(3H,m),4.59-4.55(2H,m), 4.46(2H,td,J＝7.3Hz,1.3Hz),4.19(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.5Hz),3.25(1H,d, J＝11.0Hz),3.07(1H,dt,J＝11.9Hz,8.2Hz),2.61-2.58(3H,m),2.06-1.99(2H,m),1.64-1.56 (2H,m),1.48-1.27(18H,m)；δC(125MHz；CDCl3)142.9,128.4,128.2,125.5,112.0,107.1, 81.1,77.7,75.3,68.0,65.7,59.1,54.2,35.94,31.5,29.3,27.7,27.3,26.3,25.9,24.8,24.0。
Intermediate III-19 (50.0mg,0.12mmol) was deprotected under hydrochloric acid to give N-phenylhexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-19) as a pale yellow syrup, 44.5 mg, yield: 100 percent. DeltaH(500MHz； D2O)7.39-7.36(2H,m),7.31-7.25(3H,m),4.55-4.50(2H,m),4.20(1H,dd,J＝10.5Hz,5.0 Hz),3.87-3.80(2H,m),3.66(1H,t,J＝4.2Hz),3.56-3.49(2H,m),3.39-3.34(1H,m), 3.08-3.03(1H,m),2.67(2H,t,J＝7.5Hz),1.76-1.71(2H,m),1.67-1.61(2H,m),1.45-1.33(2H, m)；δC(125MHz；D2O)143.3,128.6,128.5,125.8,70.7,68.7,68.6,67.2,62.5,55.3,54.4,34.8, 30.3,27.6,25.5,24.2。
Example 20 preparation of N-phenylheptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-20).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was carried out using compound II-1 (150.0mg,0.62mmol) and 1-bromo-7-phenylheptane (315.1mg,1.24mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-phenylheptyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-20) as a colorless syrup in 177.6 mmol, 69% yield. DeltaH(400MHz；CDCl3)7.29-7.25(2H,m),7.18-7.15(3H,m),4.59-4.55(2H,m), 4.46(2H,td,J＝7.2Hz,1.2Hz),4.20(1H,t,J＝7.7Hz),3.98(1H,t,J＝7.5Hz),3.25(1H,d, J＝11.0Hz),3.06(1H,dt,J＝11.9Hz,8.0Hz),2.61-2.57(3H,m),2.06-1.97(2H,m),1.66-1.57 (2H,m),1.44-1.27(20H,m)；δC(100MHz；CDCl3)142.9,128.4,128.2,125.5,111.0,107.1, 81.1,77.7,75.3,68.0,65.7,59.1,54.2,36.0,31.5,29.5,29.3,27.7,27.3,26.3,25.9,24.9,24.0。
Intermediate III-20 (46.0mg,0.11mmol) was deprotected under hydrochloric acid to give N-phenylheptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-20) as a pale yellow syrup, 41.1 mg, yield: 100 percent. DeltaH(500MHz； D2O)7.37-7.34(2H,m),7.30-7.23(3H,m),4.53-4.50(2H,m),4.20(1H,d,J＝4.9Hz), 3.87-3.80(2H,qm),3.62-3.61(1H,m),3.54-3.46(2H,m),3.38-3.32(1H,m),3.07-3.01(1H, m),2.63(2H,t,J＝7.4Hz),1.70(2H,s),1.65-1.59(2H,m),1.35-1.33(6H,m)；δC(125MHz； D2O)143.4,128.6,128.5,125.8,70.7,68.7,68.6,67.3,62.6,55.3,54.5,34.9,30.5,27.9,25.6, 24.3。
Example 21 preparation of N-phenyloctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-21).
Referring to the synthesis method in example 8, a nucleophilic substitution reaction was performed using compound II-1 (130.0mg,0.53mmol) and 1-bromo-8-phenyloctane (284.2mg,1.06mmol) as starting materials under the action of potassium carbonate to obtain N-alkylated intermediate N-phenyloctyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-21) as a colorless syrup, 140.7 mmol, yield 61%. DeltaH(500MHz；CDCl3)7.28-7.25(2H,m),7.18-7.15(3H,m),4.59-4.55(2H,m), 4.46(2H,td,J＝7.3Hz,1.6Hz),4.19(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.5Hz),3.25(1H,d, J＝11.0Hz),3.05(1H,dt,J＝12.3Hz,8.4Hz),2.61-2.58(3H,m),2.06-1.98(2H,m),1.62-1.56 (2H,m),1.45-1.27(22H,m)；δC(125MHz；CDCl3)142.9,128.4,128.2,125.5,111.0,107.1, 81.1,77.7,75.3,68.0,65.7,59.1,54.2,36.0,31.5,29.5,29.5,29.3,27.7,27.4,26.3,25.9,24.9, 24.0。
Intermediate III-21 (61.0mg,0.11mmol) was deprotected under hydrochloric acid to give N-phenyloctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-21) as a pale yellow syrup, 54.7 mg, yield: 100 percent. DeltaH(500MHz； D2O)7.22-7.18(2H,m),7.13-7.08(3H,m),4.53-4.51(2H,m),4.18(1H,dd,J＝9.7Hz,4.8Hz), 3.89-3.81(2H,m),3.59(1H,s),3.52-3.49(1H,m),3.41-3.37(1H,m),3.32-3.37(1H,m), 2.98-2.93(1H,m),2.51(2H,t,J＝7.5Hz),1.64-1.63(2H,m),1.52(2H,s),1.23(8H,m)； δC(125MHz；D2O)143.0,128.4,128.3,125.6,70.6,69.0,68.6,67.3,62.6,55.3,54.4,35.4, 31.1,28.8,28.6,28.5,26.0,24.5。
Example 22 preparation of N-Benzenonyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-22).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was performed using compound II-1 (200.0mg,0.82mmol) and 1-bromo-9-phenyl-nonane (462.5mg,1.64mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-phenylnonyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-22) as a colorless syrup, 201.5 mmol, yield 55%. DeltaH(500MHz；CDCl3)7.29-7.26(2H,m),7.18-7.15(3H,m),4.59-4.55(2H,m), 4.46(2H,td,J＝7.3Hz,1.5Hz),4.20(1H,t,J＝7.7Hz),3.99(1H,t,J＝7.5Hz),3.25(1H,d, J＝11.1Hz),3.06(1H,dt,J＝12.2Hz,8.3Hz),2.61-2.58(3H,m),2.06-1.98(2H,m),1.63-1.56 (2H,m),1.44-1.28(24H,m)；δC(125MHz；CDCl3)143.0,128.4,128.2,125.5,111.0,107.1, 81.1,77.7,75.3,68.0,65.8,59.1,54.3,36.0,31.5,29.6,29.6,29.5,27.7,27.4,26.3,25.9,24.9, 24.0。
Intermediate III-22 (62.0mg,0.14mmol) was deprotected under hydrochloric acid to give N-phenyloctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-22) as a pale yellow syrup, 55.9 mg, yield: 100 percent. DeltaH(500MHz； D2O)7.13-7.10(2H,m),7.05-7.00(3H,m,),4.51(2H,s),4.18(1H,d,J＝4.6Hz),3.88-3.81 (2H,m),3.59(1H,s),3.51-3.48(1H,m),3.34-3.26(2H,m),2.95-2.93(1H,m),2.45(2H,t,J＝ 7.5Hz),1.64-1.58(2H,m),1.48(2H,m),1.19(10H,m)；δC(125MHz；D2O)142.7,128.3, 128.2,125.6,70.6,69.1,68.6,67.3,62.6,55.4,54.4,35.7,31.3,29.2,29.1,28.8,26.2,24.7。
Example 23 preparation of N-hydroxypropyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-23).
Reference is made to the example 8The preparation method comprises the steps of taking a compound II-1 (200.0mg,0.82mmol) and (3-bromopropoxy) -tert-butyldimethylsilane (415.3mg,1.64mmol) as raw materials, and carrying out nucleophilic substitution reaction under the action of potassium carbonate to obtain an N-alkylated intermediate N-tert-butyldimethylsilyloxypropyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-23) which is pale yellow syrup, 204.5 mg and the yield of 57%. DeltaH(400MHz；CDCl3)4.59-4.55(2H, m),4.43(1H,td,J＝7.3Hz,1.9Hz),4.13(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.4Hz), 3.73-3.60(2H,m),3.24(1H,d,J＝11.0Hz),3.278(1H,dt,J＝12.3Hz,8.2Hz),2.58(1H,d, J＝1.5Hz),2.11-2.05(2H,m),1.71-1.65(2H,m),1.42(6H,s),1.32(3H,s),1.27(3H,s),0.88 (9H,s),0.04(6H,s)；δC(100MHz；CDCl3)110.0,107.1,81.2,77.6,75.3,68.1,65.9,61.6,59.3, 50.8,31.0,26.4,26.0,25.87,24.9,24.1,18.4,-5.3。
Intermediate III-23 (60.0mg,0.14mmol) was deprotected under hydrochloric acid to give N-hydroxypropyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-23) as a pale yellow solid in 37.1 mg, yield: 99 percent. Mp is 78-80 ℃; deltaH(400MHz；D2O)44.63-4.55(2H,m),4.26(1H,dd,J＝10.4Hz,4.8Hz),3.93-3.84(2H,m), 3.82-3.71(3H,m),3.63-3.54(3H,m),3.30-3.23(1H,m),2.12-1.96(2H,m)；δC(100MHz； D2O)70.8,69.1,68.65,67.3,62.6,56.2,55.6,52.6,26.9。
Example 24 preparation of N-hydroxybutyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-24).
Referring to the synthesis method in example 8, nucleophilic substitution reaction was performed using compound II-1 (80.0mg,0.33mmol) and (4-bromobutoxy) -tert-butyldimethylsilane (176.4mg,0.66mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-tert-butyldimethylsiloxybutyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-24) as a pale yellow syrup, 108.8 mg, 77% yield. DeltaH(400MHz；CDCl3)4.59-4.54(2H, m),4.45(1H,td,J＝7.2Hz,1.2Hz),4.18(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.6Hz),3.61(2H, t,J＝5.2Hz),3.25(1H,d,J＝11.0Hz),3.06(1H,dt,J＝12.1Hz,7.4Hz),2.60(1H,d,J＝2.4 Hz),2.08-2.02(2H,m),1.61-1.46(4H,m),1.43(6H,s),1.32(3H,s),1.27(3H,s),0.88(9H,s), 0.04(6H,s)；δC(100MHz；CDCl3)110.0,107.1,81.1,77.7,75.3,68.0,65.7,63.2,59.1,54.1, 30.7,26.3,26.0,25.9,24.9,24.1,24.0,18.4,-5.2,-5.3。
Intermediate III-24 (18.0mg,0.04mmol) was deprotected under hydrochloric acid to give N-hydroxybutyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-24) as a pale yellow syrup, 11.4 mg, yield: 100 percent. DeltaH(400MHz； D2O)4.57-4.50(2H,m),4.22(1H,dd,J＝10.0Hz,4.9Hz),3.89-3.79(2H,m),3.68-3.60(3H, m),3.56(2H,d,J＝7.4Hz),3.47-3.40(1H,m),3.17-3.10(1H,m),1.88-1.74(2H,m), 1.66-1.59(2H,m)；δC(100MHz；D2O)70.7,68.8,68.6,67.2,62.5,60.8,55.3,54.2,28.4,21.4。
Example 25 preparation of N-hydroxypentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-25).
Referring to the synthesis procedure in example 8, nucleophilic substitution reaction was performed using compound II-1 (200.0mg,0.82mmol) and (5-bromopentyloxy) -tert-butyldimethylsilane (461.3mg,1.64mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-tert-butyldimethylsilyloxypentyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-25) as a pale yellow syrup, 240.6 mg, 66% yield. DeltaH(400MHz；CDCl3)4.59-4.54(2H, m),4.45(1H,td,J＝7.3Hz,1.4Hz),4.18(1H,t,J＝7.7Hz),3.98(1H,t,J＝7.5Hz),3.59(2H, t,J＝6.5Hz),3.25(1H,d,J＝11.0Hz),3.06(1H,dt,J＝11.8Hz,8.1Hz),2.59(1H,d,J＝2.7 Hz),2.07-1.99(2H,m),1.56-1.27(18H,m),0.88(9H,s),0.03(6H,s)δC(100MHz；CDCl3) 111.1,107.1,81.1,77.7,75.3,68.0,65.8,63.2,54.3,32.9,27.6,26.3,26.0,25.9,24.9,24.0, 23.8,18.3,-5.3。
Intermediate III-25 (60.0mg,0.14mmol) was deprotected under hydrochloric acid to give N-hydroxypentyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-25) as a pale yellow syrup, 38.6 mg, yield: 100 percent. DeltaH(500MHz； D2O)4.56-4.52(1H,m),4.50(1H,t,J＝4.0Hz),4.23-4.20(1H,m),3.87-3.79(2H,m),3.66(1H, t,J＝4.0Hz),3.60(2H,t,J＝6.5Hz),3.55(2H,d,J＝7.5Hz),3.44-3.38(1H,m),3.13-3.08 (1H,m),1.84-1.71(2H,m),1.61-1.56(2H,m),1.48-1.35(2H,m)；δC(125MHz；D2O)70.7, 68.8,68.6,67.2,62.5,61.2,55.3,54.3,30.6,24.1,22.2。
Example 26 preparation of N-hydroxyhexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-26).
Referring to the synthesis method in example 8, nucleophilic substitution reaction was performed using compound II-1 (200.0mg,0.82mmol) and (6-bromohexyloxy) -tert-butyldimethylsilane (484.4mg,1.64mmol) as starting materials under the action of potassium carbonate to obtain N-alkylated intermediate N-tert-butyldimethylsilyloxyhexyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-26) as a pale yellow syrup, 259.5 mg, 69% yield. DeltaH(500MHz；CDCl3)；4.59-4.54(2H, m),4.45(1H,td,J＝7.3Hz,1.4Hz),4.18(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.5Hz),3.58 (2H,t,J＝6.7Hz),3.25(1H,d,J＝11.0Hz),3.05(1H,dt,J＝12.0Hz,8.1Hz),2.59(1H,d,J ＝2.8Hz),2.06-1.99(2H,m),1.53-1.48(2H,m),1.43-1.27(18H,m),0.89(9H,s),0.04(6H,s)； δC(125MHz；CDCl3)111.0,107.1,81.1,77.7,75.3,68.0,65.7,63.3,59.1,54.2,32.9,27.7, 26.3,26.3,26.0,25.9,25.8,24.8,24.0,18.4,-5.3。
Intermediate III-26 (60.0mg,0.13mmol) was deprotected under hydrochloric acid to give N-hydroxyhexyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-26) as a pale yellow syrup, 39.2 mg, yield: 100 percent. DeltaH(500MHz； D2O)4.57-4.50(2H,m),4.22(1H,dd,J＝10.3Hz,5.4Hz),3.88-3.80(2H,m),3.67(1H,t,J＝ 4.0Hz),3.60(2H,t,J＝6.5Hz),3.56(2H,d,J＝7.5Hz),3.44-3.38(1H,m),3.14-3.08(1H,m), 1.77(2H,m),1.57-1.55(2H,m),1.40-1.40(4H,m)；δC(125MHz；D2O)70.7,68.7,68.6,67.2, 62.5,61.5,55.3,54.4,30.9,24.4,24.5,24.2。
Example 27 preparation of N-hydroxyheptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-27).
Referring to the synthesis procedure in example 8, the compound II-1 (130.0mg,0.53mmol) and (7-bromoheptyloxy) -tert-butyldimethylsilyl silicon were usedAlkane (327.9mg,1.06mmol) as a raw material was subjected to nucleophilic substitution reaction under the action of potassium carbonate to give N-alkylated intermediate N-t-butyldimethylsilyloxyheptyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-27) as a pale yellow syrup, 143.6 mg, yield 57%. DeltaH(400MHz；CDCl3)4.58-4.53(2H, m),4.45(1H,td,J＝7.2Hz,1.5Hz),4.18(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.5Hz),3.58 (1H,t,J＝6.6Hz),3.24(1H,d,J＝11.0Hz),3.08-3.01(1H,m),2.58(1H,d,J＝2.6Hz), 2.05-1.98(2H,m),1.50-1.42(10H,m),1.34-1.23(12H,m),0.88(9H,s),0.04(6H,s)；δC(100 MHz；CDCl3)111.0,107.1,81.1,77.7,75.3,68.0,65.7,63.3,59.1,54.2,32.9,29.4,27.7, 27.4,26.3,26.0,25.9,25.8,24.9,24.0,18.4,-5.3。
Intermediate III-27 (70.0mg,0.15mmol) was deprotected under hydrochloric acid to give N-hydroxyheptyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-27) as a pale yellow syrup, 46.5 mg, yield: 100 percent. DeltaH(400MHz； CDCl3)4.57-4.50(2H,m),4.21(1H,dd,J＝10.0Hz,5.0Hz),3.87-3.79(2H,m),3.66(1H,t,J ＝3.8Hz),3.60-3.54(4H,m),3.43-3.35(1H,m),3.13-3.06(1H,m),1.75(2H,m),1.55-1.52 (2H,m),1.34(6H,m)；δC(100MHz；CDCl3)70.7,68.8,68.6,67.3,62.6,61.7,55.4,54.5,31.1. 27.9,25.6,24.7,24.3。
Example 28 preparation of N-hydroxyoctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-28).
Referring to the synthesis method in example 8, nucleophilic substitution reaction was performed using compound II-1 (100.0mg,0.41mmol) and (8-bromooctyloxy) -tert-butyldimethylsilane (265.2mg,0.82mmol) as starting materials under the action of potassium carbonate to give N-alkylated intermediate N-tert-butyldimethylsiloxyoctyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-28) as a pale yellow syrup, 133.7 mg, 47% yield. DeltaH(500MHz；CDCl3)4.59-4.54(2H, m),4.45(1H,td,J＝7.3Hz,1.5Hz),4.18(1H,t,J＝7.8Hz),3.98(1H,t,J＝7.5Hz),3.58 (1H,t,J＝6.7Hz),3.24(1H,d,J＝11.1Hz),3.05(1H,dt,J＝12.2Hz,8.3Hz),2.59(1H,d,J ＝2.8Hz),2.06-1.98(2H,m),1.51-1.43(10H,m),1.32-1.27(14H,m),0.88(9H,s),0.04(6H, s)；δC(125MHz；CDCl3)111.0,107.1,81.1,77.7,75.3,68.0,65.8,63.3,59.1,54.3,32.9,29.6, 29.5,27.7,27.4,26.3,26.0,25.9,25.8,24.9,24.0,18.4,-5.2。
Intermediate III-28 (50.0mg,0.10mmol) was deprotected under hydrochloric acid to give N-hydroxyoctyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-28) as a pale yellow syrup, 33.7 mg, yield: 100 percent. DeltaH(500MHz； CDCl3)4.57-4.50(2H,m),4.22(1H,dd,J＝10.5Hz,5.0Hz),3.88-3.80(2H,m),3.66(1H,t,J＝ 4.2Hz),3.59(2H,m),3.55(2H,m),3.43-3.35(1H,m),3.13-3.07(1H,m),1.79-1.69(2H,m), 1.55-1.53(2H,m),1.36-1.33(8H,m)；δC(125MHz；CDCl3)70.7,68.7,68.6,67.3,62.5,61.8, 55.3,54.5,31.1,28.1,28.0,25.6,24.8,24.5。
Example 29 preparation of N-hydroxynonyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-29).
The preparation method comprises the following steps:
dissolving a compound III-16 (130.0mg,0.35mmol) in 15mL of dry tetrahydrofuran, adding a tetrahydrofuran solution (0.39mL,0.39mmol) of borane in an argon atmosphere, reacting at room temperature for three hours, dropwise adding a sodium hydroxide solution until the reaction system is alkaline, adding hydrogen peroxide (0.43mL,4.24mmol), continuing to react for one hour, adding a saturated sodium thiosulfate solution to quench the reaction, adding hydrochloric acid to adjust the pH value to be neutral, removing the organic solvent under reduced pressure, adding 50mL of water, extracting for three times (50mL multiplied by 3) by using ethyl acetate, collecting a concentrated organic phase, and separating by column chromatography to obtain an intermediate N-hydroxynonyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (III-29) which is colorless syrup, 97.3 mg, yield 64%. DeltaH(400MHz；CDCl3)4.59-4.54(2H,m),4.46(1H,td,J＝7.3Hz,1.6Hz), 4.19(1H,t,J＝7.7Hz),3.97(1H,t,J＝7.6Hz,),3.62(1H,t,J＝6.6Hz),3.24(1H,d,J＝11.0 Hz),3.05(1H,dt,J＝11.9Hz,8.1Hz),2.58(1H,d,J＝2.7Hz),2.06-1.97(2H,m),1.58-1.50 (2H,m),1.43-1.27(24H,m)；δC(100MHz；CDCl3),111.0,107.1,81.1,77.7,75.3,68.0,65.7, 63.0,59.1,54.2,32.8,29.5,29.4,29.3,27.7,27.7,26.3,25.9,25.7,24.8,24.0。
Intermediate III-29 (35.0mg,0.09mmol) was dissolved in 10mL of methanol, 1mL of 6N hydrochloric acid was added, the reaction was stirred at room temperature for 1 hour, the reaction was stopped, and the solvent was evaporated under reduced pressure to give N-hydroxynonyl-1, 4-dideoxy-1, 4-imino-D-mannitol (I-29) as a white solid in 30.7 mg, yield: 99 percent. Mp is 75-76 deg.C; deltaH(500MHz；CDCl3) 4.57-4.51(2H,m),4.22(1H,dd,J＝10.4Hz,5.0Hz),3.88-3.81(2H,m),3.67(1H,t,J＝4.2 Hz),3.60(2H,t,J＝6.5Hz),3.55(2H,d,J＝7.5Hz),3.43-3.37(1H,m),3.13-3.07(1H,m), 1.79-1.69(2H,m),1.56-1.53(2H,m),1.41-1.33(10H,m)；δC(125MHz；CDCl3),77.7,68.7, 68.6,67.3,62.5,61.8,55.3,54.5,31.2,28.3,28.3,28.0,25.6,24.9,24.3。
Comparative example 1 preparation of N-methyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-1).
The preparation method comprises the following steps:
referring to the procedure of example 1, compound ii-1 (100mg,0.41mmol) was dissolved in 15mL of methanol, aqueous formaldehyde (0.11mL,1.23mmol) was added and 10mg of palladium on carbon (10%) was added under an argon atmosphere, argon was replaced with hydrogen, and the mixture was stirred at room temperature overnight, TLC showed completion of the reaction, the reaction was stopped, palladium on carbon was removed by filtration, the filtrate was concentrated, and subjected to column chromatography to obtain N-methyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (DD-1) as a pale yellow syrup, 95.9mg, yield: 91 percent. DeltaH(400MHz；CDCl3)4.61-4.55(2H,m),4.44(1H, td,J＝7.3Hz,2.0Hz),4.15(1H,t,J＝7.7Hz),4.02(1H,t,J＝7.4Hz),3.16(1H,d,J＝11.2 Hz),2.39(1H,s),2.33(3H,s),2.17(1H,dd,J＝11.2Hz,4.2Hz),1.46(3H,s),1.45(3H,s), 1.34(3H,s),1.28(3H,s)；δC(100MHz；CDCl3)110.9,107.2,81.3,77.7,75.0.,70.0,65.9,62.5, 41.6,26.3,25.7,24.4,24.2。
The intermediate DD-1(16.0mg,0.06mmol) was dissolved in 10mL of methanol, 1mL of 6N hydrochloric acid was added, the reaction was stirred at room temperature for 1 hour, and the reaction was stopped, and the solvent was evaporated under reduced pressure to give N-methyl-1, 4-dideoxy-1, 4-imino-D-mannitol as a pale yellow syrup (D-1) in 13.3 mg, yield: 100 percent; deltaH(400MHz；CDCl3)4.62-4.55(2H, m),4.24(1H,dd,J＝10.4Hz,4.8Hz),3.90-3.81(2H,m),3.66-3.61(2H,m),3.50(1H,dd,J＝ 12.4Hz,8.4Hz),3.00(3H,s)；δC(100MHz；CDCl3)70.9,69.7,68.5,67.0,62.5,58.4,39.9。
Comparative example 2 preparation of N-butyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-2).
Referring to the synthesis procedure in example 1, starting from compound ii-1 (50mg,0.21mmol) and butyraldehyde (45.4mg,0.63 mmol), the intermediate N-butyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (DD-2) was obtained as a colorless syrup, 51.1mg, yield: 87 percent. DeltaH(400MHz；CDCl3)4.59-4.54(2H,m),4.46(1H, t,J＝7.2Hz),4.20(1H,t,J＝7.6Hz),3.98(1H,t,J＝7.6Hz),3.25(1H,d,J＝10.8Hz), 3.11-3.04(H,m),2.59(1H,d,J＝2.0Hz),2.06-1.98(2H,m),1.43-1.27(16H,m),0.90(3H, t,J＝7.2Hz)；δC(100MHz；CDCl3)111.0,107.1,81.1,77.7,75.3,68.1,65.7,59.1,54.0,30.0, 26.3,25.9,24.9,24.0,20.6,14.1。
Intermediate DD-2(16.0mg,0.05mmol) was deprotected under hydrochloric acid to give N-butyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-2) as a pale yellow syrup, 13.6 mg, yield: 99 percent; deltaH(400MHz；CDCl3) 4.62-4.55(2H,m),4.24(1H,dd,J＝10.4Hz,4.8Hz),3.90-3.81(2H,m),3.66-3.61(2H,m), 3.50(1H,dd,J＝12.4Hz,8.4Hz),3.00(3H,s)；δC(100MHz；CDCl3)70.9,69.7,68.5,67.0, 62.5,58.4,39.9。
Comparative example 3 preparation of N-benzyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-3).
Referring to the synthesis in example 8, compound II-1 (100mg,0.41mmol) and benzyl bromide were used(60. mu.L, 0.49mmol) as a starting material, and nucleophilic substitution reaction under the action of sodium hydride (33mg,0.82mmol) to give an intermediate, N-benzyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (DD-3), as a colorless syrup, 107.9mg, yield: 79 percent. DeltaH(500MHz；CDCl3)7.35(2H,d,J＝7.2Hz),7.32-7.29(2H,m),7.22(1H,t,J＝ 7.2Hz),4.62-4.53(3H,m),4.46-4.42(2H,m),4.07(1H,t,J＝7.6Hz),3.14(1H,d,J＝13.6 Hz),3.04(1H,d,J＝11.3Hz),2.83(1H,d,J＝4.65Hz),2.05(1H,dd,J＝11.3Hz,4.6Hz),1.46 (3H,s),1.43(3H,s),1.36(3H,s),1.26(3H,s)；δC(125MHz；CDCl3)138.7,128.7,128.2, 126.8,111.1,107.3,81.0,77.6,75.4,67.0,65.8,59.1,58.2,26.3,24.7,23.8。
Intermediate DD-3(13.0mg,0.04mmol) was deprotected under the action of hydrochloric acid to give N-benzyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-3) as a pale yellow syrup, 11.3 mg, yield: 100 percent; deltaH((400MHz； D2O)7.58-7.51(5H,m),4.61(1H,d,J＝13.0Hz),3.96(1H,dd,J＝10.0Hz,4.8Hz), 3.89-3.78(3H,m),3.64(1H,dd,J＝12Hz,7.2Hz),3.38(1H,dd,J＝12Hz,7.2Hz)；δC(100 MHz；D2O)131.0,130.4,129.4,129.0,70.9,68.5,68.4,67.7,62.6,58.3,55.21。
Comparative example 4 preparation of N-hydroxyethyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-4).
The compound II-1 (60.0mg,0.25mmol) and (2-bromoethoxy) -tert-butyldimethylsilane (119.1mg, 0.50mmol) were used as raw materials, and nucleophilic substitution reaction was carried out under the action of potassium carbonate (103.7mg,0.75mmol), to give an intermediate N-tert-butyldimethylsilyloxyethyl-2, 3:5, 6-diacetone-1, 4-dideoxy-1, 4-imino-D-mannitol (DD-4) as a pale yellow syrup, 52.4 mg, 55% yield. DeltaH(400MHz；CDCl3)4.59-4.52(2H,m),4.46(1H,td, J＝7.2Hz,1.1Hz),4.22(1H,t,J＝7.8Hz),3.97(1H,t,J＝7.5Hz),3.75-3.66(2H,m),3.34 (1H,d,J＝11.3Hz),3.278(1H,dt,J＝12.8Hz,6.2Hz),2.71(1H,d,J＝1.7Hz),2.25-2.19 (2H,m),1.43(6H,s),1.32(3H,s),1.26(3H,s),0.88(9H,s),0.04(6H,s)；δC(100MHz； CDCl3)111.0,107.1,80.7,78.0,75.3,67.7,65.7,62.1,60.5,56.1,26.2,25.9,25.8,24.7,24.0, 18.2,-5.5。
Intermediate DD-4(30.mg,0.07mmol) was deprotected under the action of hydrochloric acid to give N-hydroxyethyl-1, 4-dideoxy-1, 4-imino-D-mannitol (D-4) as a pale yellow syrup, 18.2 mg, yield: 99 percent. DeltaH(400MHz；D2O) 4.59-4.55(2H,m),4.26(1H,d,J＝4.4Hz),3.96-3.81(5H,m),3.66-3.59(3H,m),3.35-3.32(1H, m)；δC(100MHz；D2O)70.4,69.4,68.7,67.1,62.5,56.3,56.1,55.7。
Test example
Evaluation of the glycosidase inhibitory Effect of the Compounds prepared in examples 1 to 29 and comparative examples 1 to 4, swainsonine and DIM
1) Test materials and sources
Sample preparation: the compounds (I-1) to (I-29) prepared in examples 1 to 29, the compounds (D-1) to (D-4) prepared in comparative examples 1 to 4, DIM and swainsonine.
Test materials: all 4-nitrophenol pyranoside substrates, disaccharides and glycosidases (including alpha-glucosidase, beta-glucosidase, alpha-galactosidase, beta-galactosidase, alpha-mannosidase, beta-mannosidase, alpha-L-fucosidase, trehalase, amyloglucosidase, alpha-L-rhamnosidase and beta-glucuronidase) were purchased from Sigma-Aldrich.
2) Test method
Kinetic studies were performed in 50mM sodium citrate/phosphate buffer at 37 ℃. According to different matrixes, the concentration of the prepared enzyme is 0.1-0.5 mg/mL. The activity test was carried out on 4-nitrophenol pyranoside as substrate, at the optimum pH for the activity of each enzyme. The substrate, suitably diluted enzyme solution and inhibitor (N-alkylated polyhydroxypyrrolidine) were incubated at 37 ℃ for 30 minutes, and the reaction was initiated in an ultraviolet-visible spectrophotometer and its absorbance at 400nm wavelength was measured. Finally, data analysis was performed using GraFit program [ leather barrow, r.j.grafit 4.0; erithocus Software: Staines, UK,1998 ].
3) Evaluation results
The results of the inhibitory activities of the compounds (I-1) to (I-29), the compounds (D-1) to (D-4), DIM and swainsonine of the present invention on glycosidase are shown in Table 1.
Wherein, IC50(half maximum inhibition concentration) refers to the half inhibitory concentration of the antagonist being measured. It indicates that a drug or substance (inhibitor) is inhibiting half the amount of a biological process (or a substance, such as an enzyme, cellular receptor or microorganism, that is involved in the process). In terms of apoptosis, it is understood that a certain drug induces 50% of the tumor cells at a concentration referred to as the 50% inhibitory concentration, i.e. the concentration corresponding to the ratio of apoptotic cells to total cells equal to 50%, IC50The value can be used to measure the ability of a drug to induce apoptosis, i.e., the stronger the inducing ability, the lower the value, and of course, the degree of tolerance of a cell to a drug can be inversely described.
TABLE 1
aA source of an enzyme;b-%, inhibition at a concentration of 1000. mu.M.
TABLE 1 (continuation)
aA source of an enzyme;b-%, inhibition at a concentration of 1000. mu.M.
Evaluation results show that the N-alkylated polyhydroxy pyrrolidine compounds provided by the invention all show a certain glycosidase inhibition effect. Wherein formula (I-1),The compounds shown in the formulas (I-2), (I-4), (I-8) and (I-25) all show high-selectivity alpha-mannosidase inhibitory activity, wherein the compounds shown in the formulas (I-2), (I-8) and (I-25) have high inhibitory activity on alpha-mannosidase; the compounds shown as the formulas (I-6), (I-13) and (I-14) show high selectivity to inhibit the activity of beta-galactosidase; IC when Compounds represented by formulas (I-21) and (I-22) inhibit beta-galactosidase50The values are respectively 26.7 mu M and 26.6 mu M, which shows that the two have stronger inhibition effect on beta-galactosidase; the compound represented by the formula (I-29) shows a highly selective inhibition of the activity of beta-glucuronidase.
Meanwhile, compared with DIM, the compounds shown in the formulas (I-5) - (I-7), (I-13) - (I-14), (I-17) - (I-22) and (I-28) have higher inhibitory activity on beta-galactosidase against beta-galactosidase.
The preferred embodiments of the present invention have been described above in detail, but the present invention is not limited thereto. Within the technical idea of the invention, many simple modifications can be made to the technical solution of the invention, including the combination of the technical features in any other suitable way, and these simple modifications and combinations should also be regarded as the disclosure of the invention, and all fall within the protection scope of the invention.
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910261497.5A CN110128315B (en) | 2019-04-02 | 2019-04-02 | Compound, preparation method and application thereof, glycosidase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910261497.5A CN110128315B (en) | 2019-04-02 | 2019-04-02 | Compound, preparation method and application thereof, glycosidase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110128315A CN110128315A (en) | 2019-08-16 |
| CN110128315B true CN110128315B (en) | 2021-08-20 |
Family
ID=67569089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910261497.5A Active CN110128315B (en) | 2019-04-02 | 2019-04-02 | Compound, preparation method and application thereof, glycosidase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110128315B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115433119B (en) * | 2021-06-04 | 2024-01-12 | 中国科学院化学研究所 | C5 branched 1-deoxynojirimycin derivative and preparation method and application thereof |
| CN113527174B (en) * | 2021-09-16 | 2021-12-03 | 青州市立医院 | Compound with alpha-glucosidase inhibitory activity and preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424349A1 (en) * | 1989-10-20 | 1991-04-24 | Monsanto Company | Synthesis of 1,4-dideoxy-1,4-imino-D-mannitol |
| US5773239A (en) * | 1993-10-19 | 1998-06-30 | Mount Sinai Hospital Corporation. | Mannosidase inhibitors, process for their preparation and their use as therapeutic agents |
| WO2010015815A2 (en) * | 2008-08-05 | 2010-02-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| WO2010049678A2 (en) * | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
-
2019
- 2019-04-02 CN CN201910261497.5A patent/CN110128315B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0424349A1 (en) * | 1989-10-20 | 1991-04-24 | Monsanto Company | Synthesis of 1,4-dideoxy-1,4-imino-D-mannitol |
| US5773239A (en) * | 1993-10-19 | 1998-06-30 | Mount Sinai Hospital Corporation. | Mannosidase inhibitors, process for their preparation and their use as therapeutic agents |
| WO2010015815A2 (en) * | 2008-08-05 | 2010-02-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
| WO2010049678A2 (en) * | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
Non-Patent Citations (4)
| Title |
|---|
| Bryan Winchester，等.The structural basis of the inhibition of human α-mannosidases by azafuranose analogs of mannose.《Biochemical Journal》.1993,743-749. * |
| Epimerization of C5 of an N-hydroxypyrrolidine in the synthesis of swainsonine related iminosugars;Bao-Chen Qian，等;《Org. Biomol. Chem.》;20160414;第14卷;282-289，尤其sheme2 * |
| Looking glass inhibitors: synthesis of a potent naringinase inhibitor L-DIM [1,4-dideoxy-1,4-imino-L-mannitol], the enantiomer of DIM [1,4-dideoxy-1,4-imino-D-mannitol] a potent a-D-mannosidase inhibitor;Anders E. Hakansson，等;《Tetrahedron: Asymmetry》;20071231;第18卷;4488-4498 * |
| The structural basis of the inhibition of human α-mannosidases by azafuranose analogs of mannose;Bryan Winchester，等;《Biochemical Journal》;19931231;743-749，尤其figure1、table1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110128315A (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103547577B (en) | Aquacyclic compounds as mineralocorticoid receptor antagonists | |
| JP3514490B2 (en) | Trifluoromethylpyrroloindole carboxylate derivative and method for producing the same | |
| WO2016105484A1 (en) | Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis | |
| WO2006133326A1 (en) | Inhibitors of hcv replication | |
| WO2004096806A1 (en) | Fused imidazole derivative | |
| JPS6058751B2 (en) | Proline related compounds and their production method | |
| KR20030011275A (en) | Azacyclic compounds for use in the treatment of serotonin related diseases | |
| RU2495041C2 (en) | Diester nalmefene prodrugs | |
| WO2006004200A1 (en) | Urea derivative | |
| TW201103909A (en) | Quaternary ammonium salt compound | |
| AU2006222232A1 (en) | 3,4,5-substituted piperidine compounds | |
| TWI818556B (en) | Pyridazinone compounds as PARP7 inhibitors | |
| CN110128315B (en) | Compound, preparation method and application thereof, glycosidase inhibitor | |
| ES2329004T3 (en) | NEW PROCEDURES FOR THE TREATMENT AND PREVENTION OF ILEO. | |
| WO2014146494A1 (en) | Β-aminocarbonyl compound, preparation method, pharmaceutical composition and use thereof | |
| JP2025094217A (en) | Method for treating or preventing diabetes using combined medication | |
| Ganesan et al. | Protecting group directed diversity during Mitsunobu cyclization of a carbohydrate derived diamino triol. Synthesis of novel bridged bicyclic and six-membered iminocyclitols | |
| JP4233262B2 (en) | Carbasugar amine derivatives and glycosidase inhibitors using the same | |
| US20030195229A1 (en) | Glucamine salts for treating hepatitis virus infections | |
| WO2021218997A1 (en) | Substituted five-membered aza-ring compound and use thereof in drug | |
| KR102471055B1 (en) | SGLT2/DPP4 Inhibitors and Uses Thereof | |
| WO2011043480A1 (en) | Homocysteine synthase inhibitor | |
| TW201625588A (en) | Cyclic amine derivative | |
| CA3173458A1 (en) | Novel pharmacological chaperone compounds of human acid alpha-glucosidase and the therapeutic use thereof | |
| CN116199610B (en) | Compounds having glycosidase inhibitory activity, salts and hydrates thereof, and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |